Innate Pharma (IPHA) 6-K 15 Sep 21 2021 Q2 Innate Pharma Reports First Half 2021 Financial Results and Business Update Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2021
Cover [Abstract]
Document Type	6-K
Entity Registrant Name	Innate Pharma SA
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001598599
Current Fiscal Year End Date	--12-31

Interim Condensed Consolidated

Interim Condensed Consolidated Statements of Financial Position - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	€ 103,980	€ 136,792
Short-term investments	15,341	14,845
Trade receivables and others	10,368	21,814
Total current assets	129,688	173,451
Non-current assets
Intangible assets	45,193	46,289
Property and equipment	10,891	11,694
Non-current financial assets	40,081	38,934
Other non-current assets	210	147
Trade receivables and others - non-current	34,753	29,821
Deferred tax asset	5,400	7,087
Total non-current assets	136,528	133,972
Total assets	266,217	307,423
Current liabilities
Trade payables and others	17,026	29,538
Collaboration liabilities – current portion	7,489	1,832
Financial liabilities – current portion	2,017	2,142
Deferred revenue – current portion	10,464	11,299
Provisions - current portion	5,623	676
Total current liabilities	42,619	45,488
Non-current liabilities
Collaboration liabilities – non-current portion	38,445	44,854
Financial liabilities – non-current portion	14,485	16,945
Defined benefit obligations	3,879	4,177
Deferred revenue – non-current portion	27,602	32,674
Provisions - non-current portion	226	221
Deferred tax liabilities	5,400	7,087
Total non-current liabilities	90,037	105,959
Shareholders’ equity
Share capital	3,952	3,950
Share premium	373,043	372,130
Retained earnings	(220,431)	(156,476)
Other reserves	715	355
Net income (loss)	(23,719)	(63,983)
Total shareholders’ equity	133,561	155,976
Total liabilities and shareholders’ equity	€ 266,217	€ 307,423

Interim Condensed Consolidate_2

Interim Condensed Consolidated Statements of Income (Loss) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Profit (loss) [abstract]
Revenue from collaboration and licensing agreements	€ 8,304	€ 29,841
Government financing for research expenditures	6,368	6,904
Lumoxiti Sales	1,015	0
Revenue and other income	15,686	36,745
Research and development expenses	(21,794)	(31,499)
Selling, general and administrative expenses	(19,321)	(14,490)
Operating expenses	(41,115)	(45,989)
Net income / (loss) distribution agreements	0	896
Operating income (loss)	(25,428)	(8,348)
Financial income	3,490	2,446
Financial expenses	(1,781)	(4,431)
Net financial income (loss)	1,709	(1,986)
Net income (loss) before tax	(23,719)	(10,334)
Income tax expense	0	0
Net income (loss)	€ (23,719)	€ (10,334)
Net income (loss) per share :
Weighted average number of shares (in shares)	78,997,954	78,892,031
Basic income (loss) per share (in EUR per share)	€ (0.30)	€ (0.13)
Diluted income (loss) per share (in EUR per share)	€ (0.30)	€ (0.13)

Interim Condensed Consolidate_3

Interim Condensed Consolidated Statements of Comprehensive Income (Loss) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Statement of comprehensive income [abstract]
Net income (loss)	€ (23,719)	€ (10,334)
Items which will not reclassified in the consolidated statement of income (loss)
Actuarial gains and (losses) related to defined benefit obligations	566	(131)
Elements which will be reclassified in the consolidated statement of income (loss)
Foreign currency translation gain (loss)	(178)	(13)
Other comprehensive income (loss)	388	(144)
Total comprehensive (loss)	€ (23,331)	€ (10,478)

Interim Condensed Consolidate_4

Interim Condensed Consolidated Statements of Cash Flows - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from (used in) operating activities [abstract]
Net income (loss)	€ (23,719)	€ (10,334)
Reconciliation of the net income (loss) and the cash generated from (used for) the operating activities
Depreciation and amortization, net	2,168	6,719
Employee benefits costs	268	264
Change in provision for charges	4,952	142
Share-based compensation expense	853	824
Change in valuation allowance on financial assets	(1,031)	2,536
Gains (losses) on financial assets	(443)	(48)
Change in valuation allowance on financial instruments	(170)	425
Gains on assets and other financial assets	(86)	(758)
Interest paid	160	173
Other profit or loss items with no cash effect	(1,476)	(373)
Operating cash flow before change in working capital	(18,524)	(430)
Change in working capital	(12,638)	(57,595)
Net cash generated from / (used in) operating activities:	(31,162)	(58,025)
Cash flows from (used in) investing activities [abstract]
Acquisition of intangible assets, net	(33)	(9,306)
Acquisition of property and equipment, net	(240)	(544)
Purchase of non-current financial instruments	0	(3,000)
Disposal of property and equipment	2	36
Purchase of other assets	(63)	(52)
Interest received on financial assets	86	758
Net cash generated from / (used in) investing activities:	(247)	(12,108)
Cash flows from (used in) financing activities [abstract]
Proceeds from the exercise / subscription of equity instruments	61	3
Repayment of borrowings	(1,127)	(1,029)
Net interest paid	(160)	(173)
Net cash generated / (used in) from financing activities:	(1,226)	(1,199)
Effect of the exchange rate changes	(178)	(13)
Net increase / (decrease) in cash and cash equivalents:	(32,813)	(71,345)
Cash and cash equivalents at the beginning of the year:	136,792	202,887
Cash and cash equivalents at the end of the six-months period:	103,980	131,542
Summary of changes in working capital [abstract]
Trade receivables and others (excluding rebates related to capital expenditures)	45,121	39,394
Trade receivables and others (excluding rebates related to capital expenditures), variance	6,514	(10,678)
Deferred revenue - current and non-current portion	(38,066)	(62,072)
Deferred revenue - current and non-current portion, variance	(5,907)	(27,040)
Trade payables and others (excluding payables related to capital expenditures)	(17,026)	(25,461)
Trade payables and others (excluding payables related to capital expenditures), variance	(12,493)	(10,585)
Collaboration liabilities - current and non-current portion	(45,934)	(12,012)
Collaboration liabilities - current and non-current portion, variance	(752)	(9,292)
Total change in Working Capital	(55,905)	(60,151)
Total change in Working Capital, variance	€ (12,638)	€ (57,595)

Interim Consolidated Statement

Interim Consolidated Statement of Changes in Shareholders’ Equity - EUR (€)	Total	Share capital	Share premium	Retained earnings	Other reserves	Net income (loss)	Ordinary SharesShare capital	Preferred SharesShare capital
Balance at beginning of period (in shares) at Dec. 31, 2019							78,811,114	14,507
Balance at beginning of period at Dec. 31, 2019	€ 217,416,000	€ 3,941,000	€ 369,617,000	€ (134,912,000)	€ (472,000)	€ (20,759,000)
Net loss	(10,334,000)					(10,334,000)
Actuarial (gain) loss on defined benefit obligations	(131,000)				(131,000)
Foreign currency translation loss	(13,000)			(48,000)	35,000
Total comprehensive (loss)	(10,478,000)			(48,000)	(96,000)	(10,334,000)
Allocation of prior period income (loss)	0			(20,759,000)		20,759,000
Exercise and subscription of equity instruments (in shares)							87,150
Exercise and subscription of equity instruments	3,000	4,000	(1,000)
Shared-based payment	824,000		824,000
Balance at end of period (in shares) at Jun. 30, 2020							78,898,264	14,507
Balance at end of period at Jun. 30, 2020	207,764,000	3,946,000	370,440,000	(155,719,000)	(568,000)	(10,334,000)
Balance at beginning of period (in shares) at Dec. 31, 2020							78,986,490	14,462
Balance at beginning of period at Dec. 31, 2020	155,976,000	3,950,000	372,131,000	(156,476,000)	355,000	(63,984,000)
Net loss	(23,719,000)					(23,719,000)
Actuarial (gain) loss on defined benefit obligations	566,000				566,000
Foreign currency translation loss	(178,000)			28,000	(206,000)
Total comprehensive (loss)	(23,331,000)			28,000	360,000	(23,719,000)
Allocation of prior period income (loss)	0			(63,984,000)		63,984,000
Exercise and subscription of equity instruments (in shares)							41,050	(85)
Exercise and subscription of equity instruments	61,000	2,048	59,152
Shared-based payment	853,000		853,000
Balance at end of period (in shares) at Jun. 30, 2021							79,027,540	14,377
Balance at end of period at Jun. 30, 2021	€ 133,561,000	€ 3,952,096	€ 373,043,000	€ (220,431,000)	€ 715,000	€ (23,719,000)

The Company and key events

The Company and key events	6 Months Ended
	Jun. 30, 2021
Notes To The Financial Statements [Abstract]
The Company and key events	The Company and key eventsThe company Innate Pharma SA (the “Company” and, with its subsidiary, referred to as the “Group”), is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Company’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. The company is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Since its creation, the Company has suffered losses due to its research and development ("R&D") activities. The first half of 2021 generated a net loss of 23,719 thousand euros. As of June 30, 2021, shareholders' equity amounted to 133,561 thousand euros. Subject to receiving new milestone payments related to its collaboration agreements, the Company expects to incur additional losses until, if necessary, it can generate significant revenues from its product candidates in development. The Company’s future operations are highly dependent on a combination of factors, including: (i) the success of its R&D; (ii) regulatory approval and market acceptance of the Company’s future product candidates; (iii) the timely and successful completion of additional financing; and (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new equity instruments. The activity of the Company is not subject to seasonal effects. As of June 30, 2021, the Company had one wholly owned subsidiary: Innate Pharma, Inc., incorporated under the laws of Delaware in 2009. Innate Pharma is based in Marseille, France and listed on Euronext Paris and Nasdaq in the U.S., and had 212 employees as of June 30, 2021. • Following the December 2020 announcement, Innate and AstraZeneca have successfully executed the Lumoxiti termination and transition agreement. The companies are currently in a transition period, in which Innate will remain the Biologics License Application (BLA) holder in the US until September 30, 2021. AstraZeneca will reimburse Innate for all Lumoxiti related costs and expenses, and Innate will remit proceeds from net sales to AstraZeneca. In the full year results 2020 announcement, the Company reported a contingent liability of up to $12.8 million i n its consolidated financial statements, which was linked to the split of certain manufacturing costs. As part of the termination and transition agreement, Innate and AstraZeneca agreed to split the manufacturing costs, and Innate will pay $6.2 million on April 30, 2022. This amount of $6.2 million (€5.2 million as of June 30, 2021) was booked as a provision for charges as of June 30, 2021.

Basis of presentation and state

Basis of presentation and statement of compliance	6 Months Ended
	Jun. 30, 2021
Significant Accounting Policies [Abstract]
Basis of presentation and statement of compliance	Basis of presentation and statement of complianceBasis of preparation The interim condensed consolidated financial statements as of June 30, 2021 and for the six months ended June 30, 2021 and 2020 and the related notes (together, the “interim condensed consolidated financial statements”) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase. The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board upon recommendation of the Audit Committee on September 14, 2021. They have been prepared in accordance with IAS 34, ‘Interim Financial Reporting’ as issued by the International Accounting Standard Board (“IASB”). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2020. The results of the operations for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any year in the future. Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures. and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 18.1.1 in paragraph 2.x) of the appendix to the consolidated financial statements as of December 31, 2020 of the Universal Registration Document published on April 27, 2021. Estimates and judgments which impact the condensed consolidated financial statements at June 30, 2021 are: • accounting for collaboration and licensing agreements (note 6 and 13); • estimate of the recoverable amount of the acquired and under progress licenses (note 6); • estimate of the useful life of the acquired licenses (note 6). Recently issued accounting standards and interpretations Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2021 and, as such, they have been adopted by the Company: • Amendments to IFRS 16 : Covid-19-Related Rent Concessions, published on May 22, 2020. • Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 : Interest Rate Benchmark Reform — Phase 2, published on September 26, 2019. Those amended standards have no impact on the interim condensed consolidated financial statements. Foreign currency transactions are translated into the presentation currency using the following exchange rates: June 30, 2020 December 31, 2020 June 30, 2021 €1 equals to Average rate Closing rate Average rate Closing rate Average rate Closing rate USD 1.1020 1.1198 1.1422 1.2271 1.2053 1.1884

Management of financial risks

Management of financial risks	6 Months Ended
	Jun. 30, 2021
Notes To The Financial Statements [Abstract]
Management of financial risks	Management of financial risksThe Company did not identify other risks than the ones presented in the consolidated financial statements as of and for the year ended December 31, 2020.

Cash, cash equivalents, short-t

Cash, cash equivalents, short-term investments and non-current financial assets	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Cash, cash equivalents, short-term investments and non-current financial assets	Cash, cash equivalents, short-term investments and non-current financial assets (in thousands of euro) June 30, 2021 December 31, 2020 Cash and cash equivalents 103,980 136,792 Short-term investments 15,341 14,845 Cash, cash equivalents and short-term investments 119,321 151,637 Non-current financial assets 40,081 38,934 Cash, cash equivalents and financial assets 159,402 190,571 Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts and fixed-term accounts. As of June 30, 2021, the Company also holds seven units in “SICAVs” and shares in mutual funds. The risk profiles of these funds are rated from 1 to 7 by the financial institution that manages and markets these funds (1 being the lowest risk profile).When the maturity of shares in mutual funds is longer than one year, they are classified as non-current financial instruments. Non-current financial assets generally include a guarantee of capital at the maturity date (which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as non-current due to their maturity. As of June 30, 2021 and December 31, 2020, the amount of cash, cash equivalents and financials assets denominated in US dollars amounted to €53,029 thousand and €64,654 thousand, respectively. Changes in short-term investments and non-current financial assets for the six months ended June 30, 2020 and 2021 are the following: (in thousands of euro) December 31, 2020 Acquisitions Disposals Variance of fair value through the consolidated statement of income (loss) Variation of accrued interests Foreign currency effect June 30, 2021 Short-term investments 14,845 — — 53 — 443 15,341 Non-current financial assets 38,934 — — 978 170 — 40,081 Total 53,779 — — 1,031 170 443 55,422 (in thousands of euro) December 31, 2019 Acquisitions Disposals Variance of fair value through the consolidated statement of income (loss) Variation of accrued interests Foreign currency effect June 30, 2020 Short-term investments 15,978 — — 173 — 48 16,199 Non-current financial assets 37,005 3,000 — (2,709) (425) — 36,872 Total 52,983 3,000 — (2,536) (425) 48 53,071 In the six months ended June 30, 2021 , variance of fair value through the consolidated statement of income (loss) is made of €978 thousand of unrealized gains on non-current financial assets and €53 thousand of unrealized gains on short-term investments. In the six months ended June 30, 2020, variance of fair value through the consolidated statement of income (loss) was made of €2,709 thousand of unrealized losses on non-current financial assets and €173 thousand of unrealized gains on short-term investments (see note 16).

Trade receivables and others

Trade receivables and others	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables and others	Trade receivables and others (in thousands of euro) June 30, 2021 December 31, 2020 Other receivables 68 741 Other tax credits 333 333 Prepaid expenses 5,678 6,833 VAT refund 1,729 2,208 Trade account receivables (2) 1,469 10,585 Prepayments made to suppliers 1,091 1,114 Receivables and others 10,368 21,815 Research tax credit(1) 34,753 29,821 Receivables and others - non-current 34,753 29,821 Trade receivables and others 45,121 51,636 (1) The Research tax credit is recognized as other operating income in the year to which the eligible research expenditure relates. Following the fact that the Company no longer meets the eligibility criteria for the SME status as of December 31, 2019, the CIR for the tax year 2019 and subsequent years will in principle be offset against the French corporate income tax due by the company with respect to the three following years, or refunded if necessary upon expiry of such a period. The CIR for the tax year 2019 and 2020 amounted respectively to €16,737 thousand and €13,084 thousand . The Company recorded an additional Research tax credit for the six months ended June 30, 2021 of €4,933 thousand. (2) As of December 31, 2020, this amount included a receivable of €8,400 thousands (including €1,400 thousand of value added tax) linked to the collaboration and licensing agreement signed with Sanofi in January 2016. This receivable resulted from the decision taken by Sanofi to advance IPH6101/SAR443579 towards regulatory preclinical studies for the study of a new investigational drug. This payment was received by the Company in January 2021. The net book value of the receivables is considered to be a reasonable approximation of their estimated fair value. Trade receivables and others have payment terms of less than one year. No valuation allowance was recognized on trade receivables and others as the credit risk of each debtor was considered as not significant.

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2021
Intangible assets other than goodwill [abstract]
Intangible assets	Intangible assets (in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2020 56,851 116 40,000 96,967 Acquisitions — 195 — 195 Additional considerations 2,685 — 1,000 3,685 (1) Disposals — — — — Amortizations (5,545) (2) (86) — (5,632) Transfers — — — — June 30, 2020 53,991 225 41,000 95,215 January 1, 2021 5,103 (3) 185 41,000 46,289 Acquisitions — 13 — 13 Additional considerations — — — — Disposals — — — — Amortizations (1,039) (4) (70) — (1,109) Transfers — — — — June 30, 2021 4,064 128 41,000 45,193 (1) This amount includes (i) an addition consideration of €2,685 thousand paid to Orega Biotech in April 2020 (€2,500 thousand) and June 2020 (€185 thousand) in relation to the IPH5201 rights following the first patient dosed in Phase 1 clinical trial in Mars 2020 and; (ii) an amount of €1,000 thousand to be paid to Novo Nordisk A/S following the launch of the first avdoralimab Phase 1 clinical trial. (2) This amount includes the amortization of rights related to the monalizumab (€1,686 thousand), IPH5201(€1,818 thousands) and Lumoxiti (€2,041 thousand) intangible assets. (3) The decrease of €48,888 thousand in the net book value of the Licenses acquired between June 30, 2020 and December 31, 2020 is mainly explained by the full impairment of the rights relating to Lumoxiti intangible asset, following the decision to return the commercial rights in the United States and Europe. The rights relating to the intangible asset have been fully impaired for the carrying amount of the intangible to the date of the decision, amounting to €43,529 thousand. (4) This amount correspond to the amortization of rights related to the monalizumab intangible asset (1,039 thousand). Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement Since their acquisition, monalizumab rights are amortized on a straight-line basis over the anticipated residual duration of the Phase II trials. The Company estimated that it would be fully amortized by early 2023, which is the same estimation as of December 31, 2020. The net book values of the monalizumab rights were €4,057 thousand and €5,096 thousand as of June 30, 2021 and December 31, 2020, respectively. IPH5201 (Anti-CD39) rights acquired from Orega Biotech This asset was amortized on a straight-line basis since November 1, 2018 (corresponding to the effective beginning date of the collaboration) until the date the Company expected to fulfill its commitment (end of fiscal year 2020).As of December 31, 2020, these collaboration commitments have all been fulfilled. Thus, the rights relating to IPH5201 have been fully amortized since December 31, 2020. Lumoxiti rights acquired from AstraZeneca under the 2018 AstraZeneca multi-term agreement The license was initially amortized on a straight-line basis until July 31, 2031, which corresponded to the expiration of the current composition of matter patent, not including any additional patent extensions or patents. End of November 2020, the Company decided to return the marketing rights of Lumoxiti in the United States and in Europe. Following this decision, the Company applied IAS 36 "Impairment of assets" and assessed that there was an indication of impairment sufficiently significant to result in the full impairment of the intangible asset. This depreciation was recognized with regard to the estimate of the recoverable value of Lumoxiti's intangible assets, based on expected future cash flows, determined using the marketing plan and budget approved by management, and future expenses to be exposed in particular as part of the transition plan, which was under negotiation. Thus, on the date of the decision to return the rights, the Lumoxiti rights were fully written down to their net book value as of October 31, 2020, i.e. €43,529 thousand The terms of the transition and termination agreement signed on July 2, 2021 (effective as of June 30, 2021) with AstraZeneca confirm the full depreciation of the intangible asset relating to Lumoxiti rights, in particular with regard to cash flows to be exposed (payments) by the company in the short term as part of this agreement (see note 1.2 and 18). Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S At the agreement inception, an upfront payment of €40 million for acquired rights were recorded as intangible asset. As part of this agreement, an additional amount of €1.0 million was paid in October 2020 to Novo Nordisk A / S following the launch of the first avdoralimab Phase II trial. As avdoralimab is still in clinical trial, the acquired rights are classified as intangible asset in progress. They were subject to annual impairment test. No impairment were recorded since inception. These acquired rights will be amortized when the Company obtains economic benefits. The Company has identified a potential impairment of the avdoralimab rights in the first half of 2021. The Company has therefore performed an impairment test as of June 30, 2021. The Company applied IAS 36 "Impairment of assets" and assessed whether there was any indication of impairment that could lead to the impairment of a recognized intangible asset. The Company estimated the recoverable amount of the unamortized intangible asset avdoralimab using a discounted cash flow model which confirmed that this asset was not impaired. The following main assumptions were used to determine the recoverable amount, based on the cash flows determined using the marketing plan and budget approved by management : • Cash flows are set on the basis of the development and commercialization plans and budgets approved by Management; • A discount rate of 12%; • A risk of development is taken into consideration by applying probabilities of success of reaching future phases of development to cash flows related to each development phases Those average probabilities of success of R&D projects are based on an article published in Nature Review Drug Discovery; • For the commercialization phase, selling price and sales volume are estimated on the basis of the potential market and the observed performances of comparable drugs currently on the market. Decrease in sales volume applied to the forecasted revenue once the related rights fall off-patent. In case of failure of the clinical trials in progress, the Company may have to depreciate the intangible asset corresponding to the avdoralimab rights. The Company did not identify any reasonable potential variance in the key assumptions that may generate an impairment as of June 30, 2021. Sensitivity testing regarding these following assumptions and other assumptions such as: discount rate (+1%), selling price (-25%) and growth rate at termination (-1%) were performed. These tests did not reveal any impairment. Avdoralimab does not generate economic benefits yet for the Company. In accordance with IAS 38, it will be amortized when it generates economic benefits, which can result from: • The drug candidate commercialization if Innate Pharma carries out the entire development by its own ; or, • An out-licensed agreement. If the Company commercialize the drug product on its own, it will have to determine the amortization period of the related capitalized rights. It will have to estimate their useful life, considering the date when they fall off patent. Those capitalized rights will be amortized on a straight line basis during the estimated useful life. If the Company entered in an out-licensed agreement, the Company will have to perform an analysis to determine if the control of the rights are transferred to a third-party, and thus will have to derecognize the capitalized rights. If the Company conclude that it keeps the control of the rights, it will determine their useful life and will amortize them on a straight line basis during this useful life.

Property and equipment

Property and equipment	6 Months Ended
	Jun. 30, 2021
Property, plant and equipment [abstract]
Property and equipment	Property and equipment (in thousands of euro) Lands and buildings Laboratory equipment and other In progress Total Of which finannce leases January 1, 2020 5,356 5,947 369 11,672 6,270 Acquisitions 1,152 604 129 1,885 1,152 Disposals — (36) — (36) — Depreciation (342) (745) — (1,087) (442) Transfers — — — — — June 30, 2020 6,166 5,770 498 12,434 6,980 (in thousands of euro) Lands and buildings Laboratory equipment and other In progress Total Of which right of use assets(3) January 1, 2021 5,751 5,576 367 11,694 6,423 Acquisitions — 260 — 260 — Disposals — (2) — (2) — Depreciation (393) (668) — (1,061) (535) Transfers — 4 (4) — — June 30, 2021 5,358 5,170 363 10,891 5,888

Trade payables and others

Trade payables and others	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade payables and others	Trade payables and others (in thousands of euro) June 30, 2021 December 31, 2020 Suppliers (excluding payables related to capital expenditures) 11,183 20,730 Tax and employee-related payables 5,684 8,325 Other payables 139 463 Trade payables and others (excluding payables related to capital expenditures) 17,006 29,519 Payables related to capital expenditures 20 20 Payables and others 17,026 29,538 The book value of trade payables and others is considered to be a reasonable approximation of their fair value.

Financial liabilities

Financial liabilities	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Financial liabilities	Financial liabilities (in thousands of euro) December 31, 2020 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings/leases liabilities Exchange rate variation (non cash) June 30, 2021 BPI PTZI IPH41 (1) 150 — — (150) — — BPI Refundable advance - FORCE (2) 1,454 — (1,454) — — — Lease liabilities – Building "Le Virage" 2,387 — — (255) — 2,131 Lease liabilities – Premises Innate Inc. 447 — — (18) (5) 423 Lease liabilities – Laboratory equipment 639 — — (87) — 551 Lease liabilities – Vehicles 21 — — (6) — 14 Lease liabilities - Printers 41 — — (2) — 39 Borrowing – Equipment 262 — — (25) — 236 Borrowing – Building 13,687 — — (579) — 13,107 Total 19,088 — (1,454) (1,121) (5) 16,502 (in thousands of euro) December 31, 2019 Proceeds from borrowing Proceeds from lease liabilities (non cash) Repayments of borrowings/leases liabilities Exchange rate variation (non cash) June 30, 2020 BPI PTZI IPH41 (1) 450 — — — — 450 Lease liabilities – Real estate property 418 — — (418) — — Property transaction (down-payment) (74) — — 74 — — Lease liabilities – Building "Le Virage" 1,437 — 1,120 — — 2,557 Lease liabilities – Premises Innate Inc. 496 — — (3) 9 502 Lease liabilities – Laboratory equipment 815 — — (87) — 728 Lease liabilities – Vehicles 37 — — (9) — 28 Borrowing – Equipment 319 — — (27) — 292 Borrowing – Building 14,826 — — (567) — 14,259 Total 18,723 — 1,120 (1,037) 9 18,817 (1) Interest free loan (2) As a reminder, on August 11, 2020, the Company signed a financing contract with Bpifrance Financement as part of the program set up by the French government to help develop a therapeutic solution with a preventive or curative aim against COVID-19. This funding, for a maximum amount of €6.8m, consisted of (i) an advance repayable only in the event of technical and commercial success and (ii) a non-repayable grant. This funding should be received in four successive installments. The first tranche of 1.7 million euros was paid at signing, and the other three tranches should be received after successful completion of certain clinical milestones, particularly around Phase 2 of the FORCE trial. The portion relating to the repayable advance included in this first tranche amounts to €1,454 thousand as of December 31, 2020 (including actualization). As of June 30, 2021, this financing is considered by the Company to be non-refundable , in accordance with the terms of the agreement, in light of the technical and commercial failure of the project based on the results of the Phase 2 "Force" trial evaluating avdoralimab in COVID-19, published on July 6, 2021. Finance lease obligations relate primarily to real estate property in relation to the acquisition in 2008 of the Company’s headquarters and main laboratories. They are presented in the above table net of the cash collateral paid to Sogebail, the lessor. On July 3, 2017, the Company borrowed from the Bank “Société Générale” in order to finance the construction of its future headquarters. This loan amounting to a maximum of €15,200 thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of €1,300 thousand. The loan release period was limited to August 30, 2019. On August 30, 2019, the Company drew down the remaining portion of the €15,200 thousand loan granted, for an amount of €13,900 thousand. The reimbursement of the capital has begun in August 30, 2019 and will proceed until August 30, 2031 (12 years). As of June 30, 2021, the remaining capital of the loan amounted to €13,107 thousand. The Company authorized collateral over financial “Société Générale” instruments amounting to €15,200 thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: €4,200 thousand in July 2024, €5,000 thousand in July 2027 and €6,000 thousand in July 2031. This loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and non-current financial assets are at least equal to principal as of financial year end. The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June 30, 2021: (in thousands of euro) Within 1 year From 2nd to 5th year included Over 5 years Total Lease liabilities – Building "Le Virage" 558 1,675 — 2,233 Lease liabilities – Premises Innate Inc. 83 354 8 445 Lease liabilities – Laboratory equipment 179 380 — 559 Lease liabilities – Vehicles 11 4 — 15 Lease liabilities - Printers 9 32 — — Borrowing – Equipment 57 185 — 242 Borrowing – Building 1,427 5,706 7,252 14,385 Total financial liabilities 2,324 8,336 7,260 17,920

Employee benefit

Employee benefit	6 Months Ended
	Jun. 30, 2021
Disclosure of information about defined benefit plans [abstract]
Employee benefit	Employee benefit Defined benefit obligation (in thousands of euro) June 30, 2021 December 31, 2020 Allowance for retirement defined benefit 3,411 3,713 Allowance for seniority awards 468 463 Defined benefit obligations 3,879 4,177 Amounts recognized in the statement of financial position are determined as follows (in thousand euros): As of January 1, 2020 3,760 Service cost 252 Interest costs (35) Actuarial (gain) / loss 200 As of December 31, 2020 4,177 Service cost 291 Interest costs (22) Actuarial (gain) / loss (566) As of June 30, 2021 3,879 Discount rates used by the Company to evaluate retirement benefits were based on iBoxx Corporate AA. They amounted to 0.9% and 0.50% as of June 30, 2021 and December 31, 2020, respectively.

Capital

Capital	6 Months Ended
	Jun. 30, 2021
Share Capital and Share Base Payments [Abstract]
Capital	CapitalShare capital The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. As of June 30, 2021, the Company’s share capital amounted to €3,952,096 divided into (i) 79,027,540 ordinary shares, each with a nominal value of €0.05; (ii) 6,796 “2016” preferred shares, each with a nominal value of €0.05, and (iii) 7,581 “2017” preferred shares, each with a nominal value of €0.05, respectively, fully paid up. Share capital does not include BSAs, BSAAR, AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and non-employees of the Company, but not yet exercised. On October 21, 2019 and December 30, 2019, the retention period for the “2016 free preferred shares” has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfilment of the performance criteria. Holders of “2016” preferred shares” are entitled to vote at our shareholders’ meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares. On April 3, 2021, the Group issued preferred shares “2017 free preferred shares” which will become convertible into ordinary shares following a vesting period of one year and a retention period of two years if the performance criteria and presence are met at the end of the retention period. The number of ordinary shares to which the conversion of one preferred share will entitle will be determined according to the fulfillment of the performance criteria. During the retention period, holders of the 2017 preferred shares are entitled to vote the general shareholders’ meetings, to dividends and to preferential subscription rights, as if they held the same number of ordinary shares as their number of vested 2017 free preferred shares. The 2017 preferred shares are not transferable during the retention period except under certain circumstances. After the end of the retention period, holders of all of preferred shares that have not yet converted them into our ordinary shares, are entitled to vote at our shareholders’ meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares. In the six months ended June 30, 2021, a capital increase of €2,048 (including share premium) occurred as a result of the Executive Board decision on July 19, 2021, subsequent to (i) the conversion of 85 “2016 preferred shares” in 11,050 ordinary shares and (ii) the exercise of 30,000 “2011” BSAAR, to carry out a net capital increase of €2,048 and an increase in share premium of €59,152 , broken down as follows: (i) a creation of 11,050 ordinary shares by the conversion of 85 “2016 preferred shares”, with a nominal value of €0.05 per share and (ii) a creation of 30,000 ordinary shares, with a nominal value of €0.05, for an issue price of €2.04 per share. The Company held 18,575 of its own shares as of June 30, 2021 and December 31, 2020, respectively. Date Types Number of warrants issued as of 6/30/2021 Number of warrants void as of 6/30/2021 Number of warrants exercised as of 6/30/2021 Number of warrants outstanding as of 6/30/2021 Maximum number of shares to be issued as of 6/30/2021 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 — 425,000 225,000 225,000 2.04 May 27, 2013 BSAAR 2012 146,050 — 85,950 60,100 60,100 2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 — 1,450 188,500 - October 21, 2016 AGAP Employees 2016-1 2,486 251 135 2,100 273,000 - October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — - December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 - December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — - April 3,2018 AGAP Employees 2017-1 5,725 833 — 4,892 489,200 - April 3,2018 AGAP Management 2017-1 2,400 800 — 1,600 160,000 — April 3,2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — - November 20, 2018 AGAP Perf Employees 2018-1 327,500 140,000 — 187,500 187,500 - November 20, 2018 AGAP Perf Management 2018-1 260,000 60,000 — 200,000 200,000 - January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — - April 29, 2019 AGA New Members 2017-1 25,000 — — 25,000 25,000 - July 3, 2019 AGA Bonus 2019-1 57,376 — — 57,376 57,376 - July 13, 2020 AGA Bonus 2020-1 79,861 — — 79,861 79,861 - August 5, 2020 AGAP Employees 2020-1 766,650 176,092 — 590,558 590,558 - August 5, 2020 AGAP Management 2020-1 710,000 — — 710,000 710,000 - July 21, 2020 Stock Options 2020-1 102,000 72,000 — 30,000 30,000 - November 4, 2019 AGAP 2019 Employees 2019 546,700 149,600 — 397,100 397,100 - November 4, 2019 AGAP 2019 Management 2019 355,000 30,000 — 325,000 325,000 - July 29, 2011 BSA 2011-2 225,000 — 183,060 41,940 41,940 - July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 11.00 Total as of June 30, 2021 6,398,008 642,315 1,524,934 4,230,759 5,661,417

Financial instruments recognize

Financial instruments recognized in the statement of financial position and related effect on the income statement	6 Months Ended
	Jun. 30, 2021
Disclosure of detailed information about financial instruments [abstract]
Financial instruments recognized in the statement of financial position and related effect on the income statement	Financial instruments recognized in the statement of financial position and related effect on the income statement The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. As of June 30, 2021 Book value on the statement of financial position Fair value through profit and loss (1) Amortized cost (2) Fair value Financial assets Non-current financial assets 40,081 40,081 — 40,081 Trade receivables and others 45,121 — 45,121 45,121 Short-term investments 15,341 15,341 — 15,341 Cash and cash equivalents 103,980 103,980 — 103,980 Total financial assets 204,523 159,402 45,121 204,524 Financial liabilities Financial liabilities—non-current portion 14,485 — 14,485 14,485 Financial liabilities—current portion 2,017 — 2,017 2,017 Trade payables and others 17,026 — 17,026 17,026 Total financial liabilities 33,528 — 33,528 33,528 As of December 31, 2020 Book value on the statement of financial position Fair value through profit and loss (1) Amortized Cost (2) Fair value Financial assets Non-current financial assets 38,934 38,934 — 38,934 Trade receivables and others 51,635 — 51,635 51,635 Short-term investments 14,845 14,845 — 14,845 Cash and cash equivalents 136,792 136,792 — 136,792 Total financial assets 242,206 190,571 51,635 242,206 Financial liabilities Financial liabilities—non-current portion 16,945 — 16,945 16,945 Financial liabilities—current portion 2,142 — 2,142 2,142 Trade payables and others 29,539 — 29,539 29,539 Total financial liabilities 48,626 — 48,626 48,626 ( 1) The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements. (2) The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value. In accordance with the amendments to IFRS 7, financial instruments are presented in three categories based on a hierarchy of methods used to determine fair value: Level 1: fair value determined based on quoted prices in active markets for assets or liabilities; Level 2: fair value determined on the observable database for the asset or liability concerned either directly or indirectly;

Revenue, government financing f

Revenue, government financing for research expenditures and sales	6 Months Ended
	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Revenue, government financing for research expenditures and sales	Revenue, government financing for research expenditures and salesRevenue from collaboration and licensing agreements Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca and Sanofi : (in thousands of euro) June 30, 2021 June 30, 2020 Proceeds from collaboration and licensing agreements 7,095 28,349 of which monalizumab agreement 6,095 19,636 of which IPH5201 agreement — 8,713 of which other agreement 1,000 — Invoicing of R&D costs (IPH5201 and advoralimab agreements) 1,209 1,090 Exchange gains or losses on collaboration agreement — 402 Revenue from collaboration and licensing agreements 8,304 29,841 a) Revenue recognition related to monalizumab AZ agreements and amendments Change in deferred revenue relating to monalizumab agreement: (in thousands of euro) Total As of December 31, 2019 62,657 Revenue for the six months ended June 30, 2020 (19,636) Transfer to / (from) collaboration liabilities (3,055) As of June 30, 2020 39,966 As of December 31, 2020 26,572 Revenue for the six months ended June 30, 2021 (6,095) Transfer to / (from) collaboration liabilities 188 As of June 30, 2021 20,665 Change in collaboration liabilities relating to monalizumab agreement: (in thousands of euro) Total As of December 31, 2019 21,304 Revenue for the six months ended Additions 3,055 Deductions (12,347) As of June 30, 2020 12,012 As of December 31, 2020 46,686 Revenue for the six months ended Additions 1,501 Deductions (2,253) As of June 30, 2021 45,934 The increase in collaboration liabilities relating to monalizumab agreement between June 30, 2020 and December 31, 2020 is explained by the additional payment of $50.0 million made by AstraZeneca triggered by the dosing of the first patient in the Phase 3 trial evaluating monalizumab. This payment was treated in full as a collaboration commitment ("collaboration liability" in the consolidated balance sheet) in view to the commitment linked to the contract for the Phase I/II (co-financing) and Phase III studies (amendment signed in September 2020). Consequently, this additional payment has no impact on the transaction price. b) Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement Change in deferred revenue relating to IPH5201 agreement (in thousands of euro) Total As of December 31, 2019 9,053 Revenue recognized for the six months ended June 30, 2020 (8,713) Increase in deferred revenue resulting from the $5M milestone relating to the dosage of the first phase I patient dosed 4,365 As of June 30, 2020 4,705 As of December 31, 2020, since the Company had fulfilled all of its commitments on preclinical work related to the start of Phase 1 of the IPH5201 program, the initial payment of $50.0 million and the milestone payment of $5.0 million were fully recognized in revenue. As such, the Company has not recognized any income related to the agreement with AstraZeneca on IPH5201 as of June 30, 2021. c) Schedule of variance of deferred revenue (in thousands of euro) As of December 31, 2020 Recognition in P&L Proceeds Transfer from / (to) collaboration liabilities As of June 30, 2021 Monalizumab 26,572 (6,095) — 188 20,666 IPH5201 — — — — — Preclinical molecules 17,400 — — — 17,400 Total 43,972 (6,095) — 188 38,066 (in thousands of euro) As of December 31, 2019 Recognition in P&L Proceeds Transfer from / (to) collaboration liabilities As of June 30, 2020 Monalizumab 62,657 (19,636) — (3,055) 39,966 IPH5201 9,054 (8,713) 4,365 — 4,706 Preclinical molecules 17,400 — — — 17,400 Total 89,112 (28,349) 4,365 (3,055) 62,072 The Company receives grants from the European Commission, French government and state organizations in several different forms: • Research Tax Credits; and • Investment and operating grants. As of June 30, 2021 and 2020, an estimate of the research tax credit amount for the first half period is calculated on the basis of eligible expenses over the period with a limitation representing 50% of the annual eligible subcontracting costs. As a reminder since the fiscal year 2015, the Company reached the limitation relating to the eligible subcontracting costs. However as of June 30, 2021, the limitation has not been reached regarding the level of private subcontracting costs included in the CIR calculation. The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows: (in thousands of euro) June 30, 2021 June 30, 2020 Research tax credit 4,933 6,733 Grant 1,435 171 Government financing for research expenditures 6,368 6,904 As of June 30, 2021, the total amount of grants recognized in the income statement includes an amount of €1,360 thousand representing the first tranche related to the BPI financing contract signed in August 2020 as part of the program set up by the French government to help develop a therapeutic solution with a preventive or curative aim against COVID-19. As of June 30, 2021, this financing is considered by the Company to be non-refundable , in accordance with the terms of the agreement, in light of the technical and commercial failure of the project based on the results of the Phase 2 "Force" trial evaluating avdoralimab in COVID-19, published in July 6, 2021.

Operating expenses

Operating expenses	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Operating expenses	Operating expenses (in thousands of euro) June 30, 2021 June 30, 2020 R&D SG&A Total R&D SG&A Total Subcontracting costs(1) (10,596) (75) (10,672) (14,394) — (14,394) Cost of supplies and consumable materials (1,513) (666) (2,180) (1,865) — (1,865) Personnel expenses other than share-based compensation (6,908) (5,792) (12,700) (7,644) (5,989) (13,633) Share-based compensation (219) (633) (852) (377) (447) (824) Personnel expenses (7,127) (6,425) (13,552) (8,021) (6,436) (14,457) Non-scientific advisory and consulting(2) (165) (3,293) (3,458) (20) (4,109) (4,129) Leasing and maintenance (131) (1,053) (1,184) (408) (665) (1,073) Travel expenses and meeting attendance (22) (36) (58) (145) (128) (273) Marketing, communication and public relations (44) (145) (189) (70) (725) (795) Scientific advisory and consulting(3) 51 (83) (32) (140) — (140) Other purchases and external expenses — (1,255) (1,255) 190 (911) (722) Depreciation and amortization (1,473) (719) (2,191) (6,145) (574) (6,718) Intellectual property expenses (779) 278 (500) (122) (398) (520) Other income and (expenses), net 5 (632) (627) (358) (545) (904) Termination agreement Lumoxiti - provision (4) — (5,217) (5,217) — — — Total operating expenses (21,794) (19,321) (41,115) (31,499) (14,490) (45,989) (1) The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. (2) Non-scientific advisory and consulting are services performed to support the selling, general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. (3) Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company. (4) See note 18.3.

Net income _ (loss) from distri

Net income / (loss) from distribution agreements	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Net income / (loss) from distribution agreements	Net income / (loss) from distribution agreements During the transition period which has ended on September 30, 2020, Lumoxiti products were commercialized in the US by AstraZeneca who is the owner of the regulatory approval. The Company concluded that it did not meet the criteria for being principal under IFRS 15 during the transition period. Consequently, the net result resulting from all Lumoxiti marketing’s operations was disclosed in the item line “Net income / (loss) from distribution agreements.” The Company recognized a €896 thousand net gain for the six months ended June 30, 2020, corresponding to production and marketing costs, net of sales proceeds, as invoiced by AstraZeneca in relation to Lumoxiti distribution agreement for the period. As of June 30, 2021, following the end of the transition period relating to the commercialization of Lumoxiti in the United States on September 30, 2020, the Company recognized net sales of Lumoxiti for the first half of 2021 for an amount of €1,015 thousand (see note 13.3)

Net financial income _ (loss)

Net financial income / (loss)	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Net financial income / (loss)	Net financial income / (loss) Net financial income (loss) can be analyzed as follows : (in thousands of euro) June 30, 2021 June 30, 2020 Interests on financial assets 171 343 Change in valuation allowance on financial instruments 1,040 173 Foreign exchange gains 2,185 1,929 Other financial income 94 1 Financial income 3,490 2,446 Foreign exchange losses (1,602) (1,545) Unrealized losses on financial assets — (2,712) Interest on financial liabilities (160) (173) Other financial expenses (18) (1) Financial expenses (1,781) (4,431) Net financial income (loss) 1,710 (1,985)

Income tax _ (expense)

Income tax / (expense)	6 Months Ended
	Jun. 30, 2021
Income Tax [Abstract]
Income tax / (expense)	Income tax / (expense) Due to the Company’s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. The Company did not recognize a current tax expense as at June 30, 2021 regarding a projected tax rate of nil as of December 31, 2021. As of June 30, 2021, the accumulated tax losses carryforwards of Innate Pharma SA and Innate Pharma France SAS were €339,274 thousand with no expiration date (same amount as of December 31, 2020). As of June 30, 2020, the

Commitments, contingencies and

Commitments, contingencies and litigation	6 Months Ended
	Jun. 30, 2021
Notes To The Financial Statements [Abstract]
Commitments, contingencies and litigation	Commitments, contingencies and litigationCommitments The Company has identified the following changes in off-balance sheet commitments since December 31, 2020: • non-cancellable purchase commitments as of June 30, 2021 for a total of €6,859 thousand with various CMOs. Provisions amounted to €5,849 thousand and €897 thousand as of June 30, 2021 and December 31, 2020, respectively. The amount of provisions as of June 30, 2021 mainly relates to the provision for charges relating to the payment to be made to AstraZeneca on April 30, 2022 under the Lumoxiti transition and termination agreement effective as of June 30, 2021. This payment of $6,200 thousand (€5,217 thousand as of June 30, 2021) corresponds to cost sharing, including certain manufacturing costs, between the Company and AstraZeneca. The provision thus constituted for this payment is presented under “Provision - current share” in the consolidated balance sheet. As a reminder, in December 2020, the Company announced that it was returning the commercial rights of Lumoxiti (moxetumomab pasudotox-tdfk) in the United States and Europe to AstraZeneca (MedImmune). Innate had licensed the commercial rights of Lumoxiti in the United States and Europe from AstraZeneca in October 2018. Discussions on the transition agreement were underway between the Company and AstraZeneca, in particular on the timing and costs , notably on the sharing of certain manufacturing costs, the maximum amount estimated by the Company of which could reach $12.8 million. This point was indicated in paragraph 18.b) of the appendix to the consolidated accounts as of December 31, 2020 of the Universal Registration Document published on April 27, 2021.

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2021
Related party transactions [abstract]
Related party transactions	Related party transactions Members of the Executive Board and Other Executive Members For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense: (in thousands of euro) June 30, 2021 June 30, 2020 Personnel and other short-term employee benefits 1,881 1,461 Extra pension benefits — — Share-based compensation 538 336 Executive Board Members and other Executive Members compensation 2,419 1,797 Odile Laurent was appointed as members of the Other Executive Members on January 22, 2020 as human resources director. Personnel and other short-term employee benefits correspond to amounts included in personnel expenses for the six-month periods ended June 30, 2021 and 2020 respectively. Members of the Supervisory Board The Company recognized a provision of €176 thousand for attendance fees (jetons de presence) relating to the six months ended June 30, 2021. This amount includes the compensation for the Chairman of the Supervisory Board. Related parties Novo Nordisk A/S is a shareholder, Supervisory Board member and is related to the Company by three licensing agreements related to the drug-candidates lirilumab, monalizumab and avdoralimab. Under the terms of the agreements, Novo Nordisk A/S is eligible to receive milestone payments as well as royalties on future sales. As of June 30, 2021, the Company has no liability to Novo Nordisk A/S. AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for different drug candidates (monalizumab, avdoralimab, IPH5201 and preclinical molecules) and a license agreement for the rights of the drug Lumoxiti. The payments between the two companies as well as the liabilities and receivables as of June 30, 2021 are as follows: As of June 30,2021 (in thousands of euro) Payments Assets/Liabilities Collection (AstraZeneca to the Company) / Receivables 1,711 1,813 Payments (the Company to AstraZeneca) / Liabilities (5,531) (13,368) (1) Total (3,820) (11,555) (1) This amount includes the provision for charges of $6,200 thousand (€5,217 thousand as of June 30, 2021) relating to the payment to be made to AstraZeneca on April 30, 2022 under the Lumoxiti transition and termination agreement effective as of June 30, 2021. BPI is a board member and and has granted the Company a loan (PTZI) and an interest-free advance. The loan (PTZI) is fully repaid on June 30, 2021. Regarding the repayable advance, it is considered non-repayable by the Company on June 30, 2021 in accordance with the terms specified in the financing contract signed with BPI in August 2020, in view of the technical and commercial failure of the project, given the results of the Phase 2 “Force” trial evaluating avdoralimab in COVID-19, published on July 6, 2021 (see note 9 and 13.2). Hervé Brailly is Chairman of the Supervisory Board of the Company and member of the Strategic Committee of Mi-mAbs, a company with which the Company entered into a framework service agreement on February 2, 2021 for the provision by Mi-mAbs of services in the framework of the generation of monoclonal antibodies, the production of monoclonal antibodies or associated antibodies, or the pharmacological characterization in vitro or in vivo of potential drug candidates belonging to the Company. The maximum amount of sums paid by the Company under this contract is capped at €600 thousand. The contract was concluded for a period of one year, from January 1, 2021 to December 31, 2021. Subsidiaries The business relationships between the Company and its subsidiary are governed by intra-group and commercial agreements, concluded at market standard conditions on an arm’s length basis.

Income _ (loss) per share

Income / (loss) per share	6 Months Ended
	Jun. 30, 2021
Income (Loss) Per Share [Abstract]
Income / (loss) per share	Income / (loss) per share Basic income / (loss) per share Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period. June 30, 2021 June 30, 2020 Net income/(loss) (23,719) (10,334) Weighted average number of ordinary shares in circulation 78,997,954 78,892,031 Basic income/(loss) per share (€ per share) (0.30) (0.13) Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential common shares. In thousands of euro, except for data share June 30, 2021 June 30, 2020 Net income/(loss) for the period (23,719) (10,334) Weighted average number of ordinary shares in circulation 78,997,954 78,892,031 Adjustment for share instruments — — Diluted income/(loss) per share (€ per share) (0.30) (0.13)

Events after the reporting date

Events after the reporting date	6 Months Ended
	Jun. 30, 2021
Notes To The Financial Statements [Abstract]
Events after the reporting date	Events after the reporting dateNone.

Basis of presentation and sta_2

Basis of presentation and statement of compliance (Policies)	6 Months Ended
	Jun. 30, 2021
Significant Accounting Policies [Abstract]
Basis of preparation	Basis of preparation The interim condensed consolidated financial statements as of June 30, 2021 and for the six months ended June 30, 2021 and 2020 and the related notes (together, the “interim condensed consolidated financial statements”) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase. The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board upon recommendation of the Audit Committee on September 14, 2021. They have been prepared in accordance with IAS 34, ‘Interim Financial Reporting’ as issued by the International Accounting Standard Board (“IASB”). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2020. The results of the operations for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any year in the future. Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures.
Use of judgments and estimates	Use of judgments and estimates The preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 18.1.1 in paragraph 2.x) of the appendix to the consolidated financial statements as of December 31, 2020 of the Universal Registration Document published on April 27, 2021. Estimates and judgments which impact the condensed consolidated financial statements at June 30, 2021 are: • accounting for collaboration and licensing agreements (note 6 and 13); • estimate of the recoverable amount of the acquired and under progress licenses (note 6); • estimate of the useful life of the acquired licenses (note 6).
Recently issued accounting standards and interpretations	Recently issued accounting standards and interpretations Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2021 and, as such, they have been adopted by the Company: • Amendments to IFRS 16 : Covid-19-Related Rent Concessions, published on May 22, 2020. • Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 : Interest Rate Benchmark Reform — Phase 2, published on September 26, 2019. Those amended standards have no impact on the interim condensed consolidated financial statements.
Translation of transactions denominated in foreign currency	Translation of transactions denominated in foreign currency Foreign currency transactions are translated into the presentation currency using the following exchange rates: June 30, 2020 December 31, 2020 June 30, 2021 €1 equals to Average rate Closing rate Average rate Closing rate Average rate Closing rate USD 1.1020 1.1198 1.1422 1.2271 1.2053 1.1884

Basis of presentation and sta_3

Basis of presentation and statement of compliance (Tables)	6 Months Ended
	Jun. 30, 2021
Significant Accounting Policies [Abstract]
Disclosure of effect of changes in foreign exchange rates	Foreign currency transactions are translated into the presentation currency using the following exchange rates: June 30, 2020 December 31, 2020 June 30, 2021 €1 equals to Average rate Closing rate Average rate Closing rate Average rate Closing rate USD 1.1020 1.1198 1.1422 1.2271 1.2053 1.1884

Cash, cash equivalents, short_2

Cash, cash equivalents, short-term investments and non-current financial assets (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of cash, cash equivalents and financial assets	(in thousands of euro) June 30, 2021 December 31, 2020 Cash and cash equivalents 103,980 136,792 Short-term investments 15,341 14,845 Cash, cash equivalents and short-term investments 119,321 151,637 Non-current financial assets 40,081 38,934 Cash, cash equivalents and financial assets 159,402 190,571
Disclosure of reconciliation of changes in short-term investments and non-current financial assets	Changes in short-term investments and non-current financial assets for the six months ended June 30, 2020 and 2021 are the following: (in thousands of euro) December 31, 2020 Acquisitions Disposals Variance of fair value through the consolidated statement of income (loss) Variation of accrued interests Foreign currency effect June 30, 2021 Short-term investments 14,845 — — 53 — 443 15,341 Non-current financial assets 38,934 — — 978 170 — 40,081 Total 53,779 — — 1,031 170 443 55,422 (in thousands of euro) December 31, 2019 Acquisitions Disposals Variance of fair value through the consolidated statement of income (loss) Variation of accrued interests Foreign currency effect June 30, 2020 Short-term investments 15,978 — — 173 — 48 16,199 Non-current financial assets 37,005 3,000 — (2,709) (425) — 36,872 Total 52,983 3,000 — (2,536) (425) 48 53,071

Trade receivables and others (T

Trade receivables and others (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of Trade Receivables and Others	(in thousands of euro) June 30, 2021 December 31, 2020 Other receivables 68 741 Other tax credits 333 333 Prepaid expenses 5,678 6,833 VAT refund 1,729 2,208 Trade account receivables (2) 1,469 10,585 Prepayments made to suppliers 1,091 1,114 Receivables and others 10,368 21,815 Research tax credit(1) 34,753 29,821 Receivables and others - non-current 34,753 29,821 Trade receivables and others 45,121 51,636 (1) The Research tax credit is recognized as other operating income in the year to which the eligible research expenditure relates. Following the fact that the Company no longer meets the eligibility criteria for the SME status as of December 31, 2019, the CIR for the tax year 2019 and subsequent years will in principle be offset against the French corporate income tax due by the company with respect to the three following years, or refunded if necessary upon expiry of such a period. The CIR for the tax year 2019 and 2020 amounted respectively to €16,737 thousand and €13,084 thousand . The Company recorded an additional Research tax credit for the six months ended June 30, 2021 of €4,933 thousand.

Intangible assets (Tables)

Intangible assets (Tables)	6 Months Ended
	Jun. 30, 2021
Intangible assets other than goodwill [abstract]
Disclosure of detailed information about intangible assets	(in thousands of euro) Purchased licenses Other intangible assets In progress Total January 1, 2020 56,851 116 40,000 96,967 Acquisitions — 195 — 195 Additional considerations 2,685 — 1,000 3,685 (1) Disposals — — — — Amortizations (5,545) (2) (86) — (5,632) Transfers — — — — June 30, 2020 53,991 225 41,000 95,215 January 1, 2021 5,103 (3) 185 41,000 46,289 Acquisitions — 13 — 13 Additional considerations — — — — Disposals — — — — Amortizations (1,039) (4) (70) — (1,109) Transfers — — — — June 30, 2021 4,064 128 41,000 45,193 (1) This amount includes (i) an addition consideration of €2,685 thousand paid to Orega Biotech in April 2020 (€2,500 thousand) and June 2020 (€185 thousand) in relation to the IPH5201 rights following the first patient dosed in Phase 1 clinical trial in Mars 2020 and; (ii) an amount of €1,000 thousand to be paid to Novo Nordisk A/S following the launch of the first avdoralimab Phase 1 clinical trial. (2) This amount includes the amortization of rights related to the monalizumab (€1,686 thousand), IPH5201(€1,818 thousands) and Lumoxiti (€2,041 thousand) intangible assets. (3) The decrease of €48,888 thousand in the net book value of the Licenses acquired between June 30, 2020 and December 31, 2020 is mainly explained by the full impairment of the rights relating to Lumoxiti intangible asset, following the decision to return the commercial rights in the United States and Europe. The rights relating to the intangible asset have been fully impaired for the carrying amount of the intangible to the date of the decision, amounting to €43,529 thousand. (4) This amount correspond to the amortization of rights related to the monalizumab intangible asset (1,039 thousand).

Property and equipment (Tables)

Property and equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment	(in thousands of euro) Lands and buildings Laboratory equipment and other In progress Total Of which finannce leases January 1, 2020 5,356 5,947 369 11,672 6,270 Acquisitions 1,152 604 129 1,885 1,152 Disposals — (36) — (36) — Depreciation (342) (745) — (1,087) (442) Transfers — — — — — June 30, 2020 6,166 5,770 498 12,434 6,980 (in thousands of euro) Lands and buildings Laboratory equipment and other In progress Total Of which right of use assets(3) January 1, 2021 5,751 5,576 367 11,694 6,423 Acquisitions — 260 — 260 — Disposals — (2) — (2) — Depreciation (393) (668) — (1,061) (535) Transfers — 4 (4) — — June 30, 2021 5,358 5,170 363 10,891 5,888

Trade payables and others (Tabl

Trade payables and others (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of Trade Payables and Others	(in thousands of euro) June 30, 2021 December 31, 2020 Suppliers (excluding payables related to capital expenditures) 11,183 20,730 Tax and employee-related payables 5,684 8,325 Other payables 139 463 Trade payables and others (excluding payables related to capital expenditures) 17,006 29,519 Payables related to capital expenditures 20 20 Payables and others 17,026 29,538

Financial liabilities (Tables)

Financial liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of financial liabilities per maturity	(in thousands of euro) December 31, 2020 Proceeds from borrowing Proceeds from lease liabilities and other non cash effects Repayments of borrowings/leases liabilities Exchange rate variation (non cash) June 30, 2021 BPI PTZI IPH41 (1) 150 — — (150) — — BPI Refundable advance - FORCE (2) 1,454 — (1,454) — — — Lease liabilities – Building "Le Virage" 2,387 — — (255) — 2,131 Lease liabilities – Premises Innate Inc. 447 — — (18) (5) 423 Lease liabilities – Laboratory equipment 639 — — (87) — 551 Lease liabilities – Vehicles 21 — — (6) — 14 Lease liabilities - Printers 41 — — (2) — 39 Borrowing – Equipment 262 — — (25) — 236 Borrowing – Building 13,687 — — (579) — 13,107 Total 19,088 — (1,454) (1,121) (5) 16,502 (in thousands of euro) December 31, 2019 Proceeds from borrowing Proceeds from lease liabilities (non cash) Repayments of borrowings/leases liabilities Exchange rate variation (non cash) June 30, 2020 BPI PTZI IPH41 (1) 450 — — — — 450 Lease liabilities – Real estate property 418 — — (418) — — Property transaction (down-payment) (74) — — 74 — — Lease liabilities – Building "Le Virage" 1,437 — 1,120 — — 2,557 Lease liabilities – Premises Innate Inc. 496 — — (3) 9 502 Lease liabilities – Laboratory equipment 815 — — (87) — 728 Lease liabilities – Vehicles 37 — — (9) — 28 Borrowing – Equipment 319 — — (27) — 292 Borrowing – Building 14,826 — — (567) — 14,259 Total 18,723 — 1,120 (1,037) 9 18,817 (1) Interest free loan
Disclosure of maturity analysis for non-derivative financial liabilities	The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June 30, 2021: (in thousands of euro) Within 1 year From 2nd to 5th year included Over 5 years Total Lease liabilities – Building "Le Virage" 558 1,675 — 2,233 Lease liabilities – Premises Innate Inc. 83 354 8 445 Lease liabilities – Laboratory equipment 179 380 — 559 Lease liabilities – Vehicles 11 4 — 15 Lease liabilities - Printers 9 32 — — Borrowing – Equipment 57 185 — 242 Borrowing – Building 1,427 5,706 7,252 14,385 Total financial liabilities 2,324 8,336 7,260 17,920

Employee benefit (Tables)

Employee benefit (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure of information about defined benefit plans [abstract]
Disclosure of defined benefit plans	Defined benefit obligation (in thousands of euro) June 30, 2021 December 31, 2020 Allowance for retirement defined benefit 3,411 3,713 Allowance for seniority awards 468 463 Defined benefit obligations 3,879 4,177
Disclosure of net defined benefit liability (asset)	Amounts recognized in the statement of financial position are determined as follows (in thousand euros): As of January 1, 2020 3,760 Service cost 252 Interest costs (35) Actuarial (gain) / loss 200 As of December 31, 2020 4,177 Service cost 291 Interest costs (22) Actuarial (gain) / loss (566) As of June 30, 2021 3,879

Capital (Tables)

Capital (Tables)	6 Months Ended
	Jun. 30, 2021
Share Capital and Share Base Payments [Abstract]
Disclosure of number and weighted average exercise prices of other equity instruments	The Company has issued BSAs, BSAARs, AGAs and AGAPs as follows: Date Types Number of warrants issued as of 6/30/2021 Number of warrants void as of 6/30/2021 Number of warrants exercised as of 6/30/2021 Number of warrants outstanding as of 6/30/2021 Maximum number of shares to be issued as of 6/30/2021 Exercise price per share (in €) Sept. 9, 2011 BSAAR 2011 650,000 — 425,000 225,000 225,000 2.04 May 27, 2013 BSAAR 2012 146,050 — 85,950 60,100 60,100 2.04 July 1, 2015 BSAAR 2015 1,050,382 2,720 1,940 1,045,722 1,045,722 7.20 October 21, 2016 AGAP Management 2016-1 2,000 550 — 1,450 188,500 - October 21, 2016 AGAP Employees 2016-1 2,486 251 135 2,100 273,000 - October 21, 2016 AGA Management 2016-1 50,000 — 50,000 — — - December 30, 2016 AGAP Management 2016-2 3,000 — — 3,000 333,000 - December 30, 2016 AGA Management 2016-2 250,000 — 250,000 — — - April 3,2018 AGAP Employees 2017-1 5,725 833 — 4,892 489,200 - April 3,2018 AGAP Management 2017-1 2,400 800 — 1,600 160,000 — April 3,2018 AGA Employees 2017 114,500 4,000 110,500 — — — July 3, 2018 AGA Bonus 2018-1 67,028 469 66,559 — — - November 20, 2018 AGAP Perf Employees 2018-1 327,500 140,000 — 187,500 187,500 - November 20, 2018 AGAP Perf Management 2018-1 260,000 60,000 — 200,000 200,000 - January 14, 2019 AGA Employees 2018 90,650 5,000 85,650 — — - April 29, 2019 AGA New Members 2017-1 25,000 — — 25,000 25,000 - July 3, 2019 AGA Bonus 2019-1 57,376 — — 57,376 57,376 - July 13, 2020 AGA Bonus 2020-1 79,861 — — 79,861 79,861 - August 5, 2020 AGAP Employees 2020-1 766,650 176,092 — 590,558 590,558 - August 5, 2020 AGAP Management 2020-1 710,000 — — 710,000 710,000 - July 21, 2020 Stock Options 2020-1 102,000 72,000 — 30,000 30,000 - November 4, 2019 AGAP 2019 Employees 2019 546,700 149,600 — 397,100 397,100 - November 4, 2019 AGAP 2019 Management 2019 355,000 30,000 — 325,000 325,000 - July 29, 2011 BSA 2011-2 225,000 — 183,060 41,940 41,940 - July 17, 2013 BSA 2013 237,500 — 191,140 46,360 46,360 2.36 July 16, 2014 BSA 2014 150,000 — 75,000 75,000 75,000 8.65 April 27, 2015 BSA 2015-1 70,000 — — 70,000 70,000 9.59 July 1, 2015 BSA 2015-2 14,200 — — 14,200 14,200 14.05 September 20, 2017 BSA 2017 37,000 — — 37,000 37,000 11.00 Total as of June 30, 2021 6,398,008 642,315 1,524,934 4,230,759 5,661,417

Financial instruments recogni_2

Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure of detailed information about financial instruments [abstract]
Disclosure of detailed information about financial instruments	The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. As of June 30, 2021 Book value on the statement of financial position Fair value through profit and loss (1) Amortized cost (2) Fair value Financial assets Non-current financial assets 40,081 40,081 — 40,081 Trade receivables and others 45,121 — 45,121 45,121 Short-term investments 15,341 15,341 — 15,341 Cash and cash equivalents 103,980 103,980 — 103,980 Total financial assets 204,523 159,402 45,121 204,524 Financial liabilities Financial liabilities—non-current portion 14,485 — 14,485 14,485 Financial liabilities—current portion 2,017 — 2,017 2,017 Trade payables and others 17,026 — 17,026 17,026 Total financial liabilities 33,528 — 33,528 33,528 As of December 31, 2020 Book value on the statement of financial position Fair value through profit and loss (1) Amortized Cost (2) Fair value Financial assets Non-current financial assets 38,934 38,934 — 38,934 Trade receivables and others 51,635 — 51,635 51,635 Short-term investments 14,845 14,845 — 14,845 Cash and cash equivalents 136,792 136,792 — 136,792 Total financial assets 242,206 190,571 51,635 242,206 Financial liabilities Financial liabilities—non-current portion 16,945 — 16,945 16,945 Financial liabilities—current portion 2,142 — 2,142 2,142 Trade payables and others 29,539 — 29,539 29,539 Total financial liabilities 48,626 — 48,626 48,626 ( 1) The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements. (2) The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value.

Revenue, government financing_2

Revenue, government financing for research expenditures and sales (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Disclosure of disaggregation of revenue from contracts with customers	Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca and Sanofi : (in thousands of euro) June 30, 2021 June 30, 2020 Proceeds from collaboration and licensing agreements 7,095 28,349 of which monalizumab agreement 6,095 19,636 of which IPH5201 agreement — 8,713 of which other agreement 1,000 — Invoicing of R&D costs (IPH5201 and advoralimab agreements) 1,209 1,090 Exchange gains or losses on collaboration agreement — 402 Revenue from collaboration and licensing agreements 8,304 29,841
Explanation of significant changes in contract assets and contract liabilities	Change in deferred revenue relating to monalizumab agreement: (in thousands of euro) Total As of December 31, 2019 62,657 Revenue for the six months ended June 30, 2020 (19,636) Transfer to / (from) collaboration liabilities (3,055) As of June 30, 2020 39,966 As of December 31, 2020 26,572 Revenue for the six months ended June 30, 2021 (6,095) Transfer to / (from) collaboration liabilities 188 As of June 30, 2021 20,665 Change in collaboration liabilities relating to monalizumab agreement: (in thousands of euro) Total As of December 31, 2019 21,304 Revenue for the six months ended Additions 3,055 Deductions (12,347) As of June 30, 2020 12,012 As of December 31, 2020 46,686 Revenue for the six months ended Additions 1,501 Deductions (2,253) As of June 30, 2021 45,934 Change in deferred revenue relating to IPH5201 agreement (in thousands of euro) Total As of December 31, 2019 9,053 Revenue recognized for the six months ended June 30, 2020 (8,713) Increase in deferred revenue resulting from the $5M milestone relating to the dosage of the first phase I patient dosed 4,365 As of June 30, 2020 4,705
Disclosure of variance of deferred revenue	Schedule of variance of deferred revenue (in thousands of euro) As of December 31, 2020 Recognition in P&L Proceeds Transfer from / (to) collaboration liabilities As of June 30, 2021 Monalizumab 26,572 (6,095) — 188 20,666 IPH5201 — — — — — Preclinical molecules 17,400 — — — 17,400 Total 43,972 (6,095) — 188 38,066 (in thousands of euro) As of December 31, 2019 Recognition in P&L Proceeds Transfer from / (to) collaboration liabilities As of June 30, 2020 Monalizumab 62,657 (19,636) — (3,055) 39,966 IPH5201 9,054 (8,713) 4,365 — 4,706 Preclinical molecules 17,400 — — — 17,400 Total 89,112 (28,349) 4,365 (3,055) 62,072
Disclosure of government financing for research expenditures	The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows: (in thousands of euro) June 30, 2021 June 30, 2020 Research tax credit 4,933 6,733 Grant 1,435 171 Government financing for research expenditures 6,368 6,904

Operating expenses (Tables)

Operating expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Disclosure of expenses by nature	Operating expenses (in thousands of euro) June 30, 2021 June 30, 2020 R&D SG&A Total R&D SG&A Total Subcontracting costs(1) (10,596) (75) (10,672) (14,394) — (14,394) Cost of supplies and consumable materials (1,513) (666) (2,180) (1,865) — (1,865) Personnel expenses other than share-based compensation (6,908) (5,792) (12,700) (7,644) (5,989) (13,633) Share-based compensation (219) (633) (852) (377) (447) (824) Personnel expenses (7,127) (6,425) (13,552) (8,021) (6,436) (14,457) Non-scientific advisory and consulting(2) (165) (3,293) (3,458) (20) (4,109) (4,129) Leasing and maintenance (131) (1,053) (1,184) (408) (665) (1,073) Travel expenses and meeting attendance (22) (36) (58) (145) (128) (273) Marketing, communication and public relations (44) (145) (189) (70) (725) (795) Scientific advisory and consulting(3) 51 (83) (32) (140) — (140) Other purchases and external expenses — (1,255) (1,255) 190 (911) (722) Depreciation and amortization (1,473) (719) (2,191) (6,145) (574) (6,718) Intellectual property expenses (779) 278 (500) (122) (398) (520) Other income and (expenses), net 5 (632) (627) (358) (545) (904) Termination agreement Lumoxiti - provision (4) — (5,217) (5,217) — — — Total operating expenses (21,794) (19,321) (41,115) (31,499) (14,490) (45,989) (1) The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. (2) Non-scientific advisory and consulting are services performed to support the selling, general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. (3) Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company. (4) See note 18.3.

Net financial income _ (loss) (

Net financial income / (loss) (Tables)	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Disclosure of Net Financial Income (Loss)	Net financial income (loss) can be analyzed as follows : (in thousands of euro) June 30, 2021 June 30, 2020 Interests on financial assets 171 343 Change in valuation allowance on financial instruments 1,040 173 Foreign exchange gains 2,185 1,929 Other financial income 94 1 Financial income 3,490 2,446 Foreign exchange losses (1,602) (1,545) Unrealized losses on financial assets — (2,712) Interest on financial liabilities (160) (173) Other financial expenses (18) (1) Financial expenses (1,781) (4,431) Net financial income (loss) 1,710 (1,985)

Related party transactions (Tab

Related party transactions (Tables)	6 Months Ended
	Jun. 30, 2021
Related party transactions [abstract]
Disclosure of key management personnel compensation	For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense: (in thousands of euro) June 30, 2021 June 30, 2020 Personnel and other short-term employee benefits 1,881 1,461 Extra pension benefits — — Share-based compensation 538 336 Executive Board Members and other Executive Members compensation 2,419 1,797
Disclosure of transactions between related parties	The payments between the two companies as well as the liabilities and receivables as of June 30, 2021 are as follows: As of June 30,2021 (in thousands of euro) Payments Assets/Liabilities Collection (AstraZeneca to the Company) / Receivables 1,711 1,813 Payments (the Company to AstraZeneca) / Liabilities (5,531) (13,368) (1) Total (3,820) (11,555) (1) This amount includes the provision for charges of $6,200 thousand (€5,217 thousand as of June 30, 2021) relating to the payment to be made to AstraZeneca on April 30, 2022 under the Lumoxiti transition and termination agreement effective as of June 30, 2021.

Income _ (loss) per share (Tabl

Income / (loss) per share (Tables)	6 Months Ended
	Jun. 30, 2021
Income (Loss) Per Share [Abstract]
Summary of income (loss) per share	Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period. June 30, 2021 June 30, 2020 Net income/(loss) (23,719) (10,334) Weighted average number of ordinary shares in circulation 78,997,954 78,892,031 Basic income/(loss) per share (€ per share) (0.30) (0.13) Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential common shares. In thousands of euro, except for data share June 30, 2021 June 30, 2020 Net income/(loss) for the period (23,719) (10,334) Weighted average number of ordinary shares in circulation 78,997,954 78,892,031 Adjustment for share instruments — — Diluted income/(loss) per share (€ per share) (0.30) (0.13)

The Company and key events - Th

The Company and key events - The company (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)employeesubsidiary	Jun. 30, 2020EUR (€)employee	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)
Notes To The Financial Statements [Abstract]
Net loss for the period	€ 23,719	€ 10,334
Total equity	€ 133,561	€ 207,764	€ 155,976	€ 217,416
Number of subsidiaries | subsidiary	1
Number of employees | employee	212	247

The Company and key events - Ke

The Company and key events - Key events for the six-month period ended June 30, 2021 (Details) € in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)	Jul. 06, 2021trial_cohort	Jun. 30, 2021EUR (€)
Disclosure of other provisions [line items]
Income from government grants		€ 1,435	€ 171
Technical and commercial failure of project
Disclosure of other provisions [line items]
Number of trial cohorts that did not meet primary endpoints | trial_cohort				3
Technical and commercial failure of project | BPI France, Covid-19 program, non-refundable
Disclosure of other provisions [line items]
Income from government grants		€ 1,360
2018 Lumoxiti agreement, with AstraZeneca
Disclosure of other provisions [line items]
Provision for charges	$ 6,200				€ 5,217
Estimated manufacturing costs | $	$ 12,800

Basis of presentation and sta_4

Basis of presentation and statement of compliance - Effect of Changes in Foreign Exchange Rates (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Significant Accounting Policies [Abstract]
Average rate (€1 equals to USD)	1.2053	1.1020	1.1422
Closing rate (€1 equals to USD)	1.1884	1.1198	1.2271

Cash, cash equivalents, short_3

Cash, cash equivalents, short-term investments and non-current financial assets - Cash, Cash Equivalents and Financial Assets (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Subclassifications of assets, liabilities and equities [abstract]
Cash and cash equivalents	€ 103,980	€ 136,792	€ 131,542	€ 202,887
Short-term investments	15,341	14,845
Cash, cash equivalents and short-term investments	119,321	151,637
Non-current financial assets	40,081	38,934	€ 36,872	€ 37,005
Cash, cash equivalents and financial assets	€ 159,402	€ 190,571

Cash, cash equivalents, short_4

Cash, cash equivalents, short-term investments and non-current financial assets - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)Rateshares	Jun. 30, 2020EUR (€)	Dec. 31, 2020EUR (€)
Disclosure of financial assets [Line Items]
Cash, cash equivalents and financial assets	€ 159,402		€ 190,571
Non-current financial assets, variation of fair value through the consolidated statement of income (loss)	978	€ (2,709)
Short-term investments, variation of fair value through the consolidated statement of income (loss)	€ 53	€ 173
SICAV
Disclosure of financial assets [Line Items]
Number of SICAV held | shares	7
SICAV and mutual funds | Minimum
Disclosure of financial assets [Line Items]
Risk profile rate | Rate	1
SICAV and mutual funds | Maximum
Disclosure of financial assets [Line Items]
Risk profile rate | Rate	7
Cash, cash equivalents, and financial assets denominated in US dollars
Disclosure of financial assets [Line Items]
Cash, cash equivalents and financial assets	€ 53,029		€ 64,654

Cash, cash equivalents, short_5

Cash, cash equivalents, short-term investments and non-current financial assets - Variation of Short-term Investments and Non-current Financial Assets (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Subclassifications of assets, liabilities and equities [abstract]
Beginning balance, current investments	€ 14,845	€ 15,978
Short-term investments, acquisitions	0	0
Short-term investments, disposals	0	0
Short-term investments, variation of fair value through the consolidated statement of income (loss)	53	173
Short-term investments, variation of accrued interest	0	0
Short-term investments, foreign currency effect	443	48
Ending balance, current investments	15,341	16,199
Beginning balance, non-current financial assets	38,934	37,005
Non-current financial assets, acquisitions	0	3,000
Non-current financial assets, disposals	0	0
Non-current financial assets, variation of fair value through the consolidated statement of income (loss)	978	(2,709)
Non-current financial assets, variation of accrued interest	170	(425)
Non-current financial assets, foreign currency effect	0	0
Ending balance, non-current financial assets	40,081	36,872
Beginning balance, total	53,779	52,983
Total, acquisitions	0	3,000
Total, disposals	0	0
Total, variation of fair value through the consolidated statement of income (loss)	1,031	(2,536)
Total variance of accrued interest	170	(425)
Total, foreign currency effect	443	48
Ending balance, total	€ 55,422	€ 53,071

Trade receivables and others -

Trade receivables and others - Schedule of Trade Receivables and Others (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of financial assets [Line Items]
Other receivables	€ 68	€ 741
Other tax credits	333	333
Prepaid expenses	5,678	6,833
VAT refund	1,729	2,208
Trade account receivables	1,469	10,585
Prepayments made to suppliers	1,091	1,114
Receivables and others	10,368	21,815
Research tax credit	34,753	29,821
Receivables and others - non-current	34,753	29,821
Trade receivables and others	45,121	51,636
Research tax credit 2019	16,737
Research tax credit 2020	13,084
Research tax credit, first six months 2021	€ 4,933
IPH6101 agreement, with Sanofi
Disclosure of financial assets [Line Items]
VAT refund		1,400
Trade account receivables		€ 8,400

Intangible assets - Intangible

Intangible assets - Intangible Assets (Details) - EUR (€) € in Thousands	1 Months Ended		6 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period			€ 46,289	€ 95,215	€ 96,967
Acquisitions			13		195
Additional considerations			0		3,685
Disposals			0		0
Amortizations			(1,109)		(5,632)
Transfers			0		0
Intangible assets other than goodwill at end of period	€ 95,215		45,193	46,289	95,215
Agreement with Orega Biotech
Disclosure of detailed information about intangible assets [line items]
Additional considerations	185	€ 2,500			2,685
2014 Novo Nordisk A/S monalizumab agreement
Disclosure of detailed information about intangible assets [line items]
Additional considerations					1,000
Monalizumab agreement
Disclosure of detailed information about intangible assets [line items]
Amortizations			(1,039)		(1,686)
IPH5201
Disclosure of detailed information about intangible assets [line items]
Amortizations					(1,818)
2018 Lumoxiti agreement, with AstraZeneca
Disclosure of detailed information about intangible assets [line items]
Amortizations					(2,041)
Impairment of intangible assets				43,529
Purchased licenses
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period			5,103	53,991	56,851
Acquisitions			0		0
Additional considerations			0		2,685
Disposals			0		0
Amortizations			(1,039)		(5,545)
Transfers			0		0
Intangible assets other than goodwill at end of period	53,991		4,064	5,103	53,991
Decrease in net book value of licences				48,888
Other intangible assets
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period			185	225	116
Acquisitions			13		195
Additional considerations			0		0
Disposals			0		0
Amortizations			(70)		(86)
Transfers			0		0
Intangible assets other than goodwill at end of period	225		128	185	225
In progress
Disclosure of detailed information about intangible assets [line items]
Intangible assets other than goodwill at beginning of period			41,000	41,000	40,000
Acquisitions			0		0
Additional considerations			0		1,000
Disposals			0		0
Amortizations			0		0
Transfers			0		0
Intangible assets other than goodwill at end of period	€ 41,000		€ 41,000	€ 41,000	€ 41,000

Intangible assets - Additional

Intangible assets - Additional Information (Details) - EUR (€)	1 Months Ended	6 Months Ended	35 Months Ended
	Oct. 31, 2020	Dec. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019	Jul. 31, 2017
Disclosure of detailed information about intangible assets [line items]
Total intangible assets other than goodwill		€ 46,289,000	€ 45,193,000	€ 95,215,000	€ 96,967,000
2014 Monalizumab (NKG2A) agreement, with Novo Nordisk
Disclosure of detailed information about intangible assets [line items]
Total intangible assets other than goodwill		5,096,000	4,057,000
2018 Lumoxiti agreement, with AstraZeneca
Disclosure of detailed information about intangible assets [line items]
Impairment of intangible assets		€ 43,529,000
2017 IPH5401 in-licensing agreement, with Novo Nordisk A/S
Disclosure of detailed information about intangible assets [line items]
Total intangible assets other than goodwill						€ 40,000,000
Impairment of intangible assets			€ 0
Payments for milestone	€ 1,000,000
Discount rate used in current measurement of fair value less costs of disposal			12.00%

Property and equipment - Schedu

Property and equipment - Schedule of Property, Plant and Equipment (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	€ 11,694	€ 11,672
Acquisitions	260	1,885
Disposals	(2)	(36)
Depreciation	(1,061)	(1,087)
Transfers	0	0
Property, plant and equipment at end of period	10,891	12,434
Assets under finance-lease agreements
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period		6,270
Acquisitions		1,152
Disposals		0
Depreciation		(442)
Transfers		0
Property, plant and equipment at end of period		6,980
Right-of-use assets
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	6,423
Acquisitions	0
Disposals	0
Depreciation	(535)
Transfers	0
Property, plant and equipment at end of period	5,888
Lands and buildings
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	5,751	5,356
Acquisitions	0	1,152
Disposals	0	0
Depreciation	(393)	(342)
Transfers	0	0
Property, plant and equipment at end of period	5,358	6,166
Laboratory equipment and other
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	5,576	5,947
Acquisitions	260	604
Disposals	(2)	(36)
Depreciation	(668)	(745)
Transfers	4	0
Property, plant and equipment at end of period	5,170	5,770
In progress
Disclosure of detailed information about property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	367	369
Acquisitions	0	129
Disposals	0	0
Depreciation	0	0
Transfers	(4)	0
Property, plant and equipment at end of period	€ 363	€ 498

Trade payables and others - Sch

Trade payables and others - Schedule of Trade Payables and Others (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Suppliers (excluding payables related to capital expenditures)	€ 11,183	€ 20,730
Tax and employee-related payables	5,684	8,325
Other payables	139	463
Trade payables and others (excluding payables related to capital expenditures)	17,006	29,519
Payables related to capital expenditures	20	20
Payables and others	€ 17,026	€ 29,538

Financial liabilities - Financi

Financial liabilities - Financial Liabilities Per Maturity (Details) € in Thousands	Aug. 11, 2020EUR (€)installment	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)	Dec. 31, 2020EUR (€)
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		€ 19,088	€ 18,723
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		(1,454)	1,120
Repayments of borrowings/leases liabilities		(1,121)	(1,037)
Exchange rate variation (non cash)		(5)	9
Financial liabilities at end of period		16,502	18,817
BPI Refundable advance - FORCE
Disclosure of financial liabilities [Line Items]
Proceeds from borrowing	€ 1,700
Notional amount	€ 6,800
Financing agreement, number of instalments | installment	4
Financing agreement, remaining number of instalments | installment	3
Repayable advance received				€ 1,454
BPI PTZI IPH41
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		150	450
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(150)	0
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		0	450
Lease liabilities – Real estate property
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period			418
Proceeds from borrowing			0
Proceeds from lease liabilities and other non cash effects			0
Repayments of borrowings/leases liabilities			(418)
Exchange rate variation (non cash)			0
Financial liabilities at end of period			0
Property transaction (down-payment)
Disclosure of financial liabilities [Line Items]
Proceeds from borrowing			0
Proceeds from lease liabilities and other non cash effects			0
Exchange rate variation (non cash)			0
Financial liabilities down payment at beginning of period			(74)
Repayments of borrowings, down payment			74
Financial liabilities down payment at end of period			0
BPI Refundable advance - FORCE
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		1,454
Proceeds from borrowing		0
Proceeds from lease liabilities and other non cash effects		(1,454)
Repayments of borrowings/leases liabilities		0
Exchange rate variation (non cash)		0
Financial liabilities at end of period		0
Lease liabilities – Building "Le Virage"
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		2,387	1,437
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	1,120
Repayments of borrowings/leases liabilities		(255)	0
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		2,131	2,557
Lease liabilities – Premises Innate Inc.
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		447	496
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(18)	(3)
Exchange rate variation (non cash)		(5)	9
Financial liabilities at end of period		423	502
Lease liabilities – Laboratory equipment
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		639	815
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(87)	(87)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		551	728
Lease liabilities – Vehicles
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		21	37
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(6)	(9)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		14	28
Lease liabilities - Printers
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		41
Proceeds from borrowing		0
Proceeds from lease liabilities and other non cash effects		0
Repayments of borrowings/leases liabilities		(2)
Exchange rate variation (non cash)		0
Financial liabilities at end of period		39
Borrowing – Equipment
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		262	319
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(25)	(27)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		236	292
Borrowing – Building
Disclosure of financial liabilities [Line Items]
Financial liabilities at beginning of period		13,687	14,826
Proceeds from borrowing		0	0
Proceeds from lease liabilities and other non cash effects		0	0
Repayments of borrowings/leases liabilities		(579)	(567)
Exchange rate variation (non cash)		0	0
Financial liabilities at end of period		€ 13,107	€ 14,259

Financial liabilities - Additio

Financial liabilities - Additional Information (Details) - EUR (€) € in Thousands	Aug. 30, 2019	Jul. 03, 2017	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of financial liabilities [Line Items]
Financial liabilities			€ 16,502	€ 18,817	€ 19,088	€ 18,723
Proceeds from borrowing			0	€ 0
Loan agreement with Société Générale
Disclosure of financial liabilities [Line Items]
Loan agreement, maximum borrowing capacity		€ 15,200
Financial liabilities			€ 13,107			€ 1,300	€ 1,300
Proceeds from borrowing	€ 13,900
Loan agreement, collateral		15,200
Borrowings, maturity period	12 years
Security interest on pledge of financial instruments will be released in 2024		4,200
Security interest on pledge of financial instruments will be released in 2027		5,000
Security interest on pledge of financial instruments will be released in 2031		€ 6,000
Loan agreement with Société Générale | Fixed interest rate
Disclosure of financial liabilities [Line Items]
Borrowings, interest rate			2.01%

Financial liabilities - Schedul

Financial liabilities - Schedule for Repayments of Financial Liabilities (Details) € in Thousands	Jun. 30, 2021EUR (€)
Statement Line Items [Line Items]
Undiscounted cash flows	€ 17,920
Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	2,324
From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	8,336
Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	7,260
Lease liabilities – Building "Le Virage"
Statement Line Items [Line Items]
Undiscounted cash flows	2,233
Lease liabilities – Building "Le Virage" | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	558
Lease liabilities – Building "Le Virage" | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	1,675
Lease liabilities – Building "Le Virage" | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities – Premises Innate Inc.
Statement Line Items [Line Items]
Undiscounted cash flows	445
Lease liabilities – Premises Innate Inc. | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	83
Lease liabilities – Premises Innate Inc. | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	354
Lease liabilities – Premises Innate Inc. | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	8
Lease liabilities – Laboratory equipment
Statement Line Items [Line Items]
Undiscounted cash flows	559
Lease liabilities – Laboratory equipment | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	179
Lease liabilities – Laboratory equipment | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	380
Lease liabilities – Laboratory equipment | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities – Vehicles
Statement Line Items [Line Items]
Undiscounted cash flows	15
Lease liabilities – Vehicles | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	11
Lease liabilities – Vehicles | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	4
Lease liabilities – Vehicles | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities - Printers
Statement Line Items [Line Items]
Undiscounted cash flows	0
Lease liabilities - Printers | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	9
Lease liabilities - Printers | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	32
Lease liabilities - Printers | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Borrowing – Equipment
Statement Line Items [Line Items]
Undiscounted cash flows	242
Borrowing – Equipment | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	57
Borrowing – Equipment | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	185
Borrowing – Equipment | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	0
Borrowing – Building
Statement Line Items [Line Items]
Undiscounted cash flows	14,385
Borrowing – Building | Within 1 year
Statement Line Items [Line Items]
Undiscounted cash flows	1,427
Borrowing – Building | From 2nd to 5th year included
Statement Line Items [Line Items]
Undiscounted cash flows	5,706
Borrowing – Building | Over 5 years
Statement Line Items [Line Items]
Undiscounted cash flows	€ 7,252

Employee benefit - Defined Bene

Employee benefit - Defined Benefit Obligations (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of defined benefit plans [line items]
Defined benefit obligations	€ 3,879	€ 4,177
Allowance for retirement defined benefit
Disclosure of defined benefit plans [line items]
Defined benefit obligations	3,411	3,713
Allowance for seniority awards
Disclosure of defined benefit plans [line items]
Defined benefit obligations	€ 468	€ 463

Employee benefit - Changes in P

Employee benefit - Changes in Projected Benefit Obligation (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of information about defined benefit plans [abstract]
Net defined benefit liability (asset) at beginning of period	€ 4,177	€ 3,760
Service cost	291	252
Interest costs	(22)	(35)
Actuarial (gain) / loss	(566)	200
Net defined benefit liability (asset) at end of period	€ 3,879	€ 4,177

Employee benefit - Additional I

Employee benefit - Additional Information (Details)	Jun. 30, 2021	Dec. 31, 2020
Allowance for retirement defined benefit
Disclosure of defined benefit plans [line items]
Actuarial assumption of discount rates	0.90%	0.50%

Capital - Additional Informatio

Capital - Additional Information (Details) - EUR (€)	Apr. 03, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Disclosure of changes in the share capital
Total equity		€ 133,561,000	€ 207,764,000	€ 155,976,000	€ 217,416,000
Par value per share (in EUR per share)		€ 0.05
Convertible preferred shares, vesting period (year)	1 year
Convertible preferred shares, retention period (year)	2 years
Exercise and subscription of equity instruments		€ 61,000	3,000
Share issued, price per share (in EUR per share)		€ 2.04
Number of own shares (in shares)		18,575		18,575
BSAAR 2011
Disclosure of changes in the share capital
Exercise and subscription of equity instruments (in shares)		30,000
Share capital
Disclosure of changes in the share capital
Total equity		€ 3,952,096	3,946,000	€ 3,950,000	3,941,000
Exercise and subscription of equity instruments		2,048	4,000
Share premium
Disclosure of changes in the share capital
Total equity		373,043,000	370,440,000	€ 372,131,000	€ 369,617,000
Exercise and subscription of equity instruments		€ 59,152	€ (1,000)
Ordinary Shares
Disclosure of changes in the share capital
Number of shares outstanding (in shares)		79,027,540
Par value per share (in EUR per share)		€ 0.05
Ordinary Shares | Share capital
Disclosure of changes in the share capital
Total number of shares issued (in shares)		79,027,540	78,898,264	78,986,490	78,811,114
Exercise and subscription of equity instruments (in shares)		41,050	87,150
The 2016 free preferred shares
Disclosure of changes in the share capital
Par value per share (in EUR per share)		€ 0.05
Total number of shares issued (in shares)		6,796
Number of equity instruments converted in ordinary shares (in shares)		85
Exercise and subscription of equity instruments (in shares)		11,050
The 2017 free preferred shares
Disclosure of changes in the share capital
Par value per share (in EUR per share)		€ 0.05
Total number of shares issued (in shares)		7,581

Capital - Share Based Payments

Capital - Share Based Payments (Details)	Jun. 30, 2021shares€ / shares
Warrant
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	6,398,008
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	642,315
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	1,524,934
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	4,230,759
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	5,661,417
BSAAR 2011
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	650,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	425,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	225,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	225,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 2.04
BSAAR 2012
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	146,050
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	85,950
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	60,100
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	60,100
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 2.04
BSAAR 2015
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	1,050,382
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	2,720
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	1,940
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	1,045,722
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	1,045,722
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 7.20
AGAP Management 2016-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	2,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	550
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	1,450
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	188,500
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP Employees 2016-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	2,486
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	251
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	135
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	2,100
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	273,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGA Management 2016-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	50,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	50,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP Management 2016-2
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	3,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	3,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	333,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGA Management 2016-2
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	250,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	250,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP Employees 2017-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	5,725
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	833
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	4,892
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	489,200
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP Management 2017-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	2,400
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	800
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	1,600
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	160,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGA Employees 2017
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	114,500
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	4,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	110,500
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGA Bonus 2018-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	67,028
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	469
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	66,559
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP Perf Employees 2018-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	327,500
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	140,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	187,500
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	187,500
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP Perf Management 2018-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	260,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	60,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	200,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	200,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGA Employees 2018
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	90,650
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	5,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	85,650
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	0
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	0
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGA New Members 2017-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	25,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	25,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	25,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGA Bonus 2019-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	57,376
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	57,376
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	57,376
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGA Bonus 2020-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	79,861
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	79,861
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	79,861
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP Employees 2020-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	766,650
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	176,092
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	590,558
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	590,558
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP Management 2020-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	710,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	710,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	710,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
Stock Options 2020-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	102,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	72,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	30,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	30,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP 2019 Employees 2019
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	546,700
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	149,600
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	397,100
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	397,100
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
AGAP 2019 Management 2019
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	355,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	30,000
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	325,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	325,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
BSA 2011-2
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	225,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	183,060
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	41,940
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	41,940
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 0
BSA 2013
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	237,500
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	191,140
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	46,360
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	46,360
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 2.36
BSA 2014
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	150,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	75,000
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	75,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	75,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 8.65
BSA 2015-1
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	70,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	70,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	70,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 9.59
BSA 2015-2
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	14,200
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	14,200
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	14,200
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 14.05
BSA 2017
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of free shares granted (in shares)	37,000
Number of other equity instruments forfeited in share-based payment arrangement (in shares)	0
Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)	0
Number of other equity instruments outstanding in share-based payment arrangement (in shares)	37,000
Number of other equity instruments exercisable in share-based payment arrangement (in shares)	37,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares	€ 11

Financial instruments recogni_3

Financial instruments recognized in the statement of financial position and related effect on the income statement - Summary of Detailed Information About Financial Instruments (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of detailed information about financial instruments [line items]
Financial assets	€ 204,523	€ 242,206
Financial assets, fair value	204,524	242,206
Financial liabilities	33,528	48,626
Financial liabilities, fair value	33,528	48,626
Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	33,528	48,626
Financial liabilities—non-current portion
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	14,485	16,945
Financial liabilities, fair value	14,485	16,945
Financial liabilities—non-current portion | Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities—non-current portion | Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	14,485	16,945
Financial liabilities—current portion
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	2,017	2,142
Financial liabilities, fair value	2,017	2,142
Financial liabilities—current portion | Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Financial liabilities—current portion | Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	2,017	2,142
Trade payables and others
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	17,026	29,539
Financial liabilities, fair value	17,026	29,539
Trade payables and others | Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	0	0
Trade payables and others | Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	17,026	29,539
Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	159,402	190,571
Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	45,121	51,635
Non-current financial assets
Disclosure of detailed information about financial instruments [line items]
Financial assets	40,081	38,934
Financial assets, fair value	40,081	38,934
Non-current financial assets | Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	40,081	38,934
Non-current financial assets | Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	0
Trade receivables and others
Disclosure of detailed information about financial instruments [line items]
Financial assets	45,121	51,635
Financial assets, fair value	45,121	51,635
Trade receivables and others | Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	0
Trade receivables and others | Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	45,121	51,635
Short-term investments
Disclosure of detailed information about financial instruments [line items]
Financial assets	15,341	14,845
Financial assets, fair value	15,341	14,845
Short-term investments | Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	15,341	14,845
Short-term investments | Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	0
Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Financial assets	103,980	136,792
Financial assets, fair value	103,980	136,792
Cash and cash equivalents | Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	103,980	136,792
Cash and cash equivalents | Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial assets	€ 0	€ 0

Revenue, government financing_3

Revenue, government financing for research expenditures and sales - Revenue from Collaboration and Licensing Agreements (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	€ 8,304	€ 29,841
Collaboration and licensing agreements
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	7,095	28,349
Monalizumab agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	6,095	19,636
IPH5201 agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	0	8,713
Other agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	1,000	0
Invoicing of R&D costs (IPH5201 and advoralimab agreements)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	1,209	1,090
Exchange gains or losses on collaboration agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from collaboration and licensing agreements	€ 0	€ 402

Revenue, government financing_4

Revenue, government financing for research expenditures and sales - Change in Deferred Revenue and Collaboration Liabilities (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Deferred revenue
Deferred Revenue, Roll Forward [Abstract]
Contract liabilities at beginning of period	€ 43,972	€ 89,112
Revenue for the current period	(6,095)	(28,349)
Contract liabilities at end of period	38,066	62,072
Collaboration Liabilities, Roll Forward [Abstract]
Contract liabilities at beginning of period	43,972	89,112
Contract liabilities at end of period	38,066	62,072
Deferred revenue | 2015 monalizumab agreement, with AstraZeneca
Deferred Revenue, Roll Forward [Abstract]
Contract liabilities at beginning of period	26,572	62,657
Revenue for the current period	(6,095)	(19,636)
Transfer to / (from) collaboration liabilities	188	(3,055)
Contract liabilities at end of period	20,665	39,966
Collaboration Liabilities, Roll Forward [Abstract]
Contract liabilities at beginning of period	26,572	62,657
Contract liabilities at end of period	20,665	39,966
Deferred revenue | IPH5201 agreement, with AstraZeneca
Deferred Revenue, Roll Forward [Abstract]
Contract liabilities at beginning of period		9,053
Revenue for the current period		(8,713)
Revenue from contracts with customers, milestone		4,365
Contract liabilities at end of period		4,705
Collaboration Liabilities, Roll Forward [Abstract]
Contract liabilities at beginning of period		9,053
Contract liabilities at end of period		4,705
Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca
Deferred Revenue, Roll Forward [Abstract]
Contract liabilities at beginning of period	46,686	21,304
Contract liabilities at end of period	45,934	12,012
Collaboration Liabilities, Roll Forward [Abstract]
Contract liabilities at beginning of period	46,686	21,304
Additions	1,501	3,055
Deductions	(2,253)	(12,347)
Contract liabilities at end of period	€ 45,934	€ 12,012

Revenue, government financing_5

Revenue, government financing for research expenditures and sales - Additional Information (Details) € in Thousands, $ in Millions	Dec. 07, 2020USD ($)	Mar. 31, 2020USD ($)	Jan. 31, 2019USD ($)	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research tax credit, maximum percentage of annual subcontracting costs eligible for calculation basis				0.50
Grant | €				€ 1,435	€ 171
Lumoxiti Sales | €				1,015	€ 0
BPI Refundable advance - FORCE
Disclosure of disaggregation of revenue from contracts with customers [line items]
Grant | €				€ 1,360
2015 monalizumab agreement, with AstraZeneca
Disclosure of disaggregation of revenue from contracts with customers [line items]
Milestone payment received | $	$ 50
IPH5201 agreement, with AstraZeneca
Disclosure of disaggregation of revenue from contracts with customers [line items]
Milestone payment received | $		$ 5
Receipts from co-development agreement and option agreement | $			$ 50

Revenue, government financing_6

Revenue, government financing for research expenditures and sales - Schedule of Variance of Deferred Revenue (Details) - Deferred revenue - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	€ 43,972	€ 89,112
Recognition in P&L	(6,095)	(28,349)
Proceeds	0	4,365
Transfer from / (to) collaboration liabilities	188	(3,055)
Contract liabilities at end of period	38,066	62,072
Monalizumab
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	26,572	62,657
Recognition in P&L	(6,095)	(19,636)
Proceeds	0	0
Transfer from / (to) collaboration liabilities	188	(3,055)
Contract liabilities at end of period	20,666	39,966
IPH5201
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	0	9,054
Recognition in P&L	0	(8,713)
Proceeds	0	4,365
Transfer from / (to) collaboration liabilities	0	0
Contract liabilities at end of period	0	4,706
Preclinical molecules
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract liabilities at beginning of period	17,400	17,400
Recognition in P&L	0	0
Proceeds	0	0
Transfer from / (to) collaboration liabilities	0	0
Contract liabilities at end of period	€ 17,400	€ 17,400

Revenue, government financing_7

Revenue, government financing for research expenditures and sales - Government Financing for Research Expenditures (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Research tax credit	€ 4,933	€ 6,733
Grant	1,435	171
Government financing for research expenditures	€ 6,368	€ 6,904

Operating expenses - Expenses b

Operating expenses - Expenses by Nature (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Statement Line Items [Line Items]
Subcontracting costs	€ (10,672)	€ (14,394)
Cost of supplies and consumable materials	(2,180)	(1,865)
Personnel expenses other than share-based compensation	(12,700)	(13,633)
Share-based compensation	(852)	(824)
Personnel expenses	(13,552)	(14,457)
Non-scientific advisory and consulting	(3,458)	(4,129)
Leasing and maintenance	(1,184)	(1,073)
Travel expenses and meeting attendance	(58)	(273)
Marketing, communication and public relations	(189)	(795)
Scientific advisory and consulting	(32)	(140)
Other purchases and external expenses	(1,255)	(722)
Depreciation and amortization	(2,191)	(6,718)
Intellectual property expenses	(500)	(520)
Other income and (expenses), net	(627)	(904)
Termination agreement Lumoxiti - provision	(5,217)	0
Operating expenses	(41,115)	(45,989)
Operating expenses | R&D
Statement Line Items [Line Items]
Subcontracting costs	(10,596)	(14,394)
Cost of supplies and consumable materials	(1,513)	(1,865)
Personnel expenses other than share-based compensation	(6,908)	(7,644)
Share-based compensation	(219)	(377)
Personnel expenses	(7,127)	(8,021)
Non-scientific advisory and consulting	(165)	(20)
Leasing and maintenance	(131)	(408)
Travel expenses and meeting attendance	(22)	(145)
Marketing, communication and public relations	(44)	(70)
Scientific advisory and consulting	51	(140)
Other purchases and external expenses	0	190
Depreciation and amortization	(1,473)	(6,145)
Intellectual property expenses	(779)	(122)
Other income and (expenses), net	5	(358)
Termination agreement Lumoxiti - provision	0	0
Operating expenses	(21,794)	(31,499)
Operating expenses | SG&A
Statement Line Items [Line Items]
Subcontracting costs	(75)	0
Cost of supplies and consumable materials	(666)	0
Personnel expenses other than share-based compensation	(5,792)	(5,989)
Share-based compensation	(633)	(447)
Personnel expenses	(6,425)	(6,436)
Non-scientific advisory and consulting	(3,293)	(4,109)
Leasing and maintenance	(1,053)	(665)
Travel expenses and meeting attendance	(36)	(128)
Marketing, communication and public relations	(145)	(725)
Scientific advisory and consulting	(83)	0
Other purchases and external expenses	(1,255)	(911)
Depreciation and amortization	(719)	(574)
Intellectual property expenses	278	(398)
Other income and (expenses), net	(632)	(545)
Termination agreement Lumoxiti - provision	(5,217)	0
Operating expenses	€ (19,321)	€ (14,490)

Operating expenses - Additional

Operating expenses - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)employee	Jun. 30, 2020EUR (€)employee
Analysis of income and expense [abstract]
Personnel expenses other than share-based compensation | €	€ 12,700	€ 13,633
Number of employees | employee	212	247

Net income _ (loss) from dist_2

Net income / (loss) from distribution agreements (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net income / (loss) distribution agreements	€ 0	€ 896
Lumoxiti Sales	1,015	0
2018 Lumoxiti agreement, with AstraZeneca
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net income / (loss) distribution agreements		€ 896
Lumoxiti Sales	€ 1,015

Net financial income _ (loss) -

Net financial income / (loss) - Disclosure of Net Financial Income (Loss) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Analysis of income and expense [abstract]
Interests on financial assets	€ 171	€ 343
Change in valuation allowance on financial instruments	1,040	173
Foreign exchange gains	2,185	1,929
Other financial income	94	1
Financial income	3,490	2,446
Foreign exchange losses	(1,602)	(1,545)
Unrealized losses on financial assets	0	(2,712)
Interest on financial liabilities	(160)	(173)
Other financial expenses	(18)	(1)
Financial expenses	(1,781)	(4,431)
Net financial income (loss)	€ 1,710	€ (1,985)

Income tax _ (expense) (Details

Income tax / (expense) (Details) € in Thousands, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)	Dec. 31, 2021	Dec. 31, 2020EUR (€)	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)
Disclosure Of Income Tax [Line Items]
Current tax expense (income)	€ 0
Unused tax losses with no expiration date	€ 339,274			€ 339,274
Unused tax losses subject to expiration		€ 5,114		€ 5,114	$ 5,727	$ 5,727
Expiration period		20 years
Forecast
Disclosure Of Income Tax [Line Items]
Applicable tax rate			0.00%

Commitments, contingencies an_2

Commitments, contingencies and litigation (Details) € in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021EUR (€)	Dec. 31, 2020EUR (€)
Disclosure of contingent liabilities [table]
Non-cancellable off-balance sheet purchase commitments		€ 6,859
Total provisions		5,849	€ 897
2018 Lumoxiti agreement, with AstraZeneca
Disclosure of contingent liabilities [table]
Provision for charges	$ 6,200	€ 5,217
Estimated manufacturing costs | $	$ 12,800

Related party transactions - Ke

Related party transactions - Key Management Personnel Compensation (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Related party transactions [abstract]
Personnel and other short-term employee benefits	€ 1,881	€ 1,461
Extra pension benefits	0	0
Share-based compensation	538	336
Executive Board Members and other Executive Members compensation	€ 2,419	€ 1,797

Related party transactions - Ad

Related party transactions - Additional Information (Details) € in Thousands	Feb. 02, 2021EUR (€)	Jun. 30, 2021EUR (€)licensing_agreement
Disclosure of transactions between related parties [Line Items]
Provision for attendance fees		€ 176
Amounts payable, related party transactions		€ 13,368
Novo Nordisk A/S
Disclosure of transactions between related parties [Line Items]
Number of licensing agreements | licensing_agreement		3
Amounts payable, related party transactions		€ 0
Mi-mAbs
Disclosure of transactions between related parties [Line Items]
Maximum services to be received, related party transactions	€ 600
Service agreement, period	1 year

Related party transactions - Re

Related party transactions - Related Party Transactions (Details) - 6 months ended Jun. 30, 2021 € in Thousands, $ in Thousands	EUR (€)	USD ($)	EUR (€)
Disclosure of transactions between related parties [Line Items]
Collection	€ 1,711
Receivables			€ 1,813
Payments	(5,531)
Liabilities			(13,368)
Net collection (payments)	€ (3,820)
Net receivables (liabilities)			(11,555)
2018 Lumoxiti agreement, with AstraZeneca
Disclosure of transactions between related parties [Line Items]
Provision for charges		$ 6,200	€ 5,217

Income _ (loss) per share - Sum

Income / (loss) per share - Summary of Income (Loss) Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income (Loss) Per Share [Abstract]
Net income (loss)	€ (23,719)	€ (10,334)
Weighted average number of ordinary shares in circulation (in shares)	78,997,954	78,892,031
Basic income/(loss) per share (in EUR per share)	€ (0.30)	€ (0.13)
Adjustment for share instruments (in shares)	0	0
Diluted income/(loss) per share (in EUR per share)	€ (0.30)	€ (0.13)

Uncategorized Items - _IXDS

Label	Element	Value
Deferred income	ifrs-full_DeferredIncome	€ 43,973,000
Deferred income	ifrs-full_DeferredIncome	89,112,000
Trade and other receivables	ifrs-full_TradeAndOtherReceivables	28,716,000
Trade and other receivables	ifrs-full_TradeAndOtherReceivables	51,635,000
Trade and other payables	ifrs-full_TradeAndOtherPayables	36,047,000
Trade and other payables	ifrs-full_TradeAndOtherPayables	29,519,000
Collaboration Liabilities	inpha_CollaborationLiabilities	21,304,000
Collaboration Liabilities	inpha_CollaborationLiabilities	46,686,000
Change In Working Capital	inpha_ChangeInWorkingCapital	68,543,000
Change In Working Capital	inpha_ChangeInWorkingCapital	€ 117,746,000